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ABCE1 - ATP binding cassette E1 
AIDS - Acquired Immune Deficiency Syndrome  
APOBEC - Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
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NLS – Nuclear Localization Signal 
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PIC – pre_integration Complex 
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Pol - Polymerase 
PR - Protease 
PRD – Proline Rich Domain 
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RT – Reverse Transcription 
SL – Stem Loop 
Tat – Transcription Activator 
TRIM5 - Tripartite motif-containing protein 5 
tRNA Lys3 - lysyl-tRNA synthetase (LysRS) complex 
TSG – Tumour suppressor Gene 










Recent efforts in treatment of HIV-1 have led to major breakthrough in drug development 
against the virus. While treatments like combined antiretroviral therapy (cART) lead to 
undetectable virus loads, it does not eradicate the infection completely. More so the long-
term therapy and emergence of drug resistance still remains a challenge. This thesis is based 
on our study which looks at the HIV-1 structural protein Gag. The precursor Gag has till now 
avoided the limelight as a drug target due to its dynamic and flexible nature. In this study we 
have for the first time shown a robust and inexpensive method for producing recombinant 
full length precursor Gag expressed in E.coli. Further optimization to the method helped us 
in acquiring large amounts of Gag protein for biophysical analysis. The thermodynamic 
analysis of the interaction between precursor Gag and RNA is the first of its kind and gives 
us intricate details of the evolution of Gag-RNA interaction during virus maturation. The 
results from this analysis also helps us in understanding of how the virus selectively 
packages two copies of genomic RNA into a mature virion for successive infection. During 
the maturation process the precursor Gag protein undergoes proteolytic cleavage and 
rearranges itself to accommodate formation of various individual mature domains. Using 
the purified recombinant Gag, we have made a major headway into identifying certain 
conditions that will help us in obtaining the complex structural details of the Gag protein 
molecule. These structural details will be valuable in identifying motifs that can act as drug 
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Chapter 1: Introduction 
1.1  Discovery of HIV 
The first clinical report of acquired immunodeficiency syndrome (AIDS) was made in 1981 in 
the United States, and the discovery of HIV as the primary cause of AIDS was made in 1983 
by two different groups lead by Dr. Robert Gallo and Dr. Luc Montagnier respectively 5,6. 
AIDS causes a spectrum of conditions that are the result of opportunistic infections such as 
tuberculosis, pneumocystis pneumonia, and Kaposi’s sarcoma due to the weakening of the 
immune system. 
1.2 HIV/AIDS Epidemic 
Currently the United Nations estimates the number of HIV infected people in the world to 
be around 36.9 million with annually 2 million new infection cases and around 1.2 million 
HIV-related deaths occurring every year (UNAIDS report, 2014). The two strains of HIV are 
categorized into HIV-1 and HIV-2; where HIV-1 is the most common strain affecting people 
around the world and HIV-2 is mainly prevalent in west Africa 7. HIV is an enveloped RNA 
virus that belongs to the lentivirus genus of retroviruses. Phylogenetically, HIV-1 is divided 
into three distinct groups; Group M (main) is the most common type of HIV, which accounts 
for more than 90% of cases, the M group is further divided into clades or subtype (A-F) 
based on nucleotide sequences derived from multiple subgenomic regions (gag, pol, 
and env) of the same isolates or on full-length genome sequence analysis. Group O (outlier) 
are confined to Central and West Africa and Group N strains are found in Cameroon 8. For 
the purpose of our study we looked at the more widespread HIV-1 strain. 
1.3 HIV Life cycle 
HIV-1 genome is primarily a coding RNA and consists of nine genes that encode for the 
structural proteins (Gag, Pol, and Env), regulatory proteins (Tat and Rev) and the accessory 




Figure 1.1:  
 HIV-1 Genome sequence displaying various coding and overlapping sequences. (Gag - 
groupspecific  antigen, pol -polymerase gene, env -envelope, tat-Transactivator, rev-
Regulation of viral expression, vif-Viral infectivity, vpr-Viral protein R, vpu- Viral protein U, 
nef-Negative-regulation factor) 
HIV-1 only codes for 16 proteins from these 9 genes 9 described in table 1.1, it needs to 
utilize various host cell factors extensively during replication. 
Table 1: Major HIV genes and their encoded structural and regulatory proteins 
Gene name Protein products 
gag Matrix, Capsid, Nucleocapsid, p6 
pol Reverse transciptase, Rnase H, Integrase, Protease 














This replication cycle can be broken down into the following stages: 
 
Figure 1.2: 
 Major steps involved in  HIV-1 life cycle:CD4 receptor and CCR5 co-receptor binding; fusion 
and release of capsid in the cytoplasm; uncoating of capsid; release of HIV RNA; reverse 
transcription and formation of the pre-integration complex (PIC); translocation to the 
nucleus. DNA integration into the nucleus and translation into viral RNA, transcription and 
translation into Gag. Assembly into immature particle and budding from the host cell, 
followed by maturation into an infectious virus. 
1.3.1 Entry 
The first step of the viral replication cycle starts with the binding of virus to the host cell and 
stops with the fusion of viral and host cell membranes. This involves interaction between 
the viral and the host cell, which occurs by the mediation through the viral envelope protein 
(Env) 10. Attachment of the virus to the host cell can be nonspecific or specific subjected to 
the interaction between the Env and cell surface heparin sulfate proteoglycans or Env and 
α4β7 integrin respectively 11,12. In dendritic cells this interaction is more specific to receptors 
that recognise patterns such as intercellular adhesion molecular 3-grabbing non-integrin 13. 
The next step involves interaction between the viral gp120, a subunit of the Env and the 
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host cell CD4 molecule along with co receptors (CCR5 or CXCR4) present on the surface of 
the host cell. This gp120 consists of five variable loops (V1-V5), the loop structures in which 
are formed by a disulphide bond at its base with the exception of V5. These loops are 
present on the surface of gp120 and are major requirements for immune evasion and co 
receptor binding 14.  The HIV envelope interaction with CD4 and brings about structural 
changes in gp120 particularly the V1-V3 loops. In the following steps, the rearrangement of 
the variable loops leads to the gp120-CXCR4/CCR5 interaction that results in viral-host cell 
membrane fusion. After fusion and attachment of the host cell and viral membranes, the 
viral capsid is released into the cytoplasm.  
1.3.2 Un-coating 
The process of un-coating the HIV-1 core releases the viral genome and accessory proteins 
into the cytoplasm. The viral core consists of the conical capsid (CA) encapsulating the viral 
RNA genome, and proteins associated with the RNA such as the nucleocapsid (NC), reverse 
transcriptase (RT) and integrase (IN).  This un-coating process is highly regulated and relies 
on various host cell interactions. Any delay or premature dissociation of the outer capsid 
shell can have detrimental effects on virus infectivity 15. For example, a host cell cytoplasmic 
protein, cyclophillin A (CypA), interacts with Gag to form a stable and essential complex with 
CA in the virus. This CypA and CA interaction helps in stabilising the capsid core and 
prevents premature un-coating. Any disruption in CypA incorporation in the virus leads to a 
reduction in infectivity 16. CypA can also modulate viral uncoating through another 
cytoplasmic protein known as Tripartite motif protein 5-alpha (TRIM5α). Trim5α is a 
cytoplasmic protein which recognizes CA and disrupts viral uncoating in species specific 
manner 17. Even though the rhesus macaque form of Trim5α inhibits HIV-1 replication and 
the human homolog does not, a single amino acid mutation causes Trim5α to gain 
restriction of HIV-1 18,19. The binding of Trim5α and Gag CA is largely promoted by the 
elongated antiparallel structure of Trim5α that provides optimal spacing and orientation. 20 
1.3.3 Reverse transcription 
The viral RNA genome is reverse transcribed into a double stranded DNA by the enzyme 
reverse transcriptase (RT). The high rates of HIV-1 mutation are mainly due to the infidelity 
7 
 
of the RT enzyme. Reverse Transcription in HIV is initiated by annealing of partially unwound 
tRNALys3 to the primer-binding site (PBS), present near the 5’ untranslated region of genomic 
RNA. The NC domain of the structural protein Gag enhances the tRNALys3 annealing during 
retroviral DNA synthesis by promoting the unwinding of tRNA 21. DNA synthesis creates an 
RNA-DNA duplex that acts as a substrate for RNase H, which degrades the viral RNA. This 
degradation causes exposure of the newly synthesized minus-strand DNA 22. At either end of 
the viral RNA are direct repeats known as R, these repeats help in transfer of the newly 
synthesized minus-strand DNA to the 3’ end of the viral RNA. Elongation of viral cDNA is 
carried out by the RT enzyme, during which NC facilitates annealing of complementary 
strand during strand transfer 23. Degradation of viral RNA is carried out alongside cDNA 
synthesis by RNase H and is partially suppressed at a purine rich sequence in the RNA 
genome called polypurine tract. This polypurine tract sequence serves as the primer for plus 
strand DNA synthesis. The final pro-viral DNA is longer than the degraded template virus 
RNA and contains additional sequences as compared with each end of the RNA. These 
sequences are similar in each viral DNA and are termed long terminal repeats (LTRs) 22. 
1.3.4 Integration 
Integration is facilitated by IN, which is introduced into the host cells during infection along 
with RT, the viral RNA and the viral core 24. After being reverse transcribed, viral DNA forms 
a pre integration complex (PIC) with both viral and cellular proteins. Cytoplasmic dynein 
proteins help in transfer of PIC to the nucleus, where HIV-1 uses proteins containing nuclear 
localization signals (NLS) to gain access to the host DNA 25. IN along with other cellular 
factors help in integration of viral genome into the host DNA 26. Although integration occurs 
precisely at the termini of viral DNA with the recognition of LTRs, the locations within the 
host genome where the pro-viral DNA is inserted are not as specific.  
1.3.5 Transcription 
The integrated HIV-1 provirus acts as a transcription template which is regulated at 
transcriptional and post-transcriptional levels 27. Incompletely processed cellular transcripts 
usually are degraded in the nucleus, to overcome these mechanisms HIV-1 expresses 
regulatory factors which aid in the transport of intron-containing viral RNA out from the 
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nucleus.   Larger mRNA species (~9 kb or 4kb) which are the template for the synthesis of 
Gag and Pol or Env, respectively, are transported and expressed with the help of Rev. The 
4kb viral mRNA class is also responsible for the synthesis of viral accessory proteins. 
Completely spliced smaller mRNA (~1.8 kb) species encoding Tat, Rev and Nef are 
transported with the help of an endogenous cellular pathway in the absence of Rev 27. Viral 
protein Tat regulates the transcription process and in the absence of Tat, transcription 
elongation is highly restricted 28,29.   . 
1.3.6 Assembly  
As the infection advances, full-length un-spliced transcripts are synthesized which act as 
genomic RNA for the virus, as well as the template mRNA for translation of  Gag-pol 
polyprotein 30. The incompletely processed spliced mRNA are exported from the nucleus 
through a Rev-dependent pathway and used for translation of Env and other accessory 
proteins (Vif, Vpu and Vpr) , whereas complete spliced mRNA transcripts use mRNA export 
route 31. Translation of Gag and Gag-Pol and other accessory proteins occurs in the 
cytoplasm on the cytosolic polysomes and need to be trafficked to sites of assembly on the 
plasma membrane. For trafficking to the plasma membrane, Gag interacts with the cellular 
motor protein KIF4 32,33, RNA-binding protein Staufen 34 and other constituents of the 
intracellular trafficking pathway such as clathrin-associated adaptor AP-2 and AP-3 35,36. The 
Gag-membrane binding requires myristoylation and presence of a basic patch of residues on 
the MA domain that takes part in the binding 37. Gag interacts with numerous host cell as 
well as viral factors during virus assembly; and these interactions will be discussed in more 
detail in subsequent sections. 
1.3.7 Budding and Maturation 
In order to detach from the membranous neck connecting the virion to plasma membrane 
of the host cell, HIV-1 and numerous other enveloped viruses hijack the host cell protein 
sorting machinery known as ESCRT complexes. 38. This Gag-ESCRT interaction, is carried out 
through its highly conserved PTAP and LYP(X)nL sequence motifs present on the Gag p6 
domain. It is predicted that Gag with its PTAP motif present on the late domain, mimics the 
role of Hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) protein to recruit 
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TSG101 (ESCRT I) 39. Any disruption in the TSG101-p6 domain interaction causes severe 
budding defects, highlighting the importance of the endosomal sorting pathway in 
retrovirus budding 40.  
The protease present within the pol gene is responsible for cleavage of the Gag-Pol 
precursor. It is assumed that the protease (PR) encoded is only active in its dimer form and 
the Gag-Pol must itself dimerize with a second precursor gene 41. Precise structural 
maturation of the virus particle is controlled by sequential proteolysis of Gag. The PR 
recognition sites are cleaved at different rates, with a 400-fold difference between the 
fastest (SP1 and NC) and the slowest (CA and SP1) cleavage sites 42,43. The difference in the 
cleavage rates is essential for an ordered intra-virion cleavage process, which is vital for 
maturation and infectivity of the virus43,44,45. The role of these individual cleavage sites has 
been extensively studied by introducing mutations at the cleavage sites 46. Cleavage of MA 
and CA is necessary for separation of CA from MA, as MA is membrane associated47.  
Figure 1.3:  
Maturation of the immature viral 
particle following cleavage. (a) p55 
into (b) p41 and p15; (c) p15 cleaved into 
p6 and p9; and (d) p41 cleaved into p17 
and p25. (e) Finally, p25 is cleaved into 
p24 and p2, whereas p9 is cleaved into 
p7 and p1 yielding the mature viral 
proteins p17, p24, p2, p7, and p6 1.  
The immature CA disruption is brought 
about by cleavage at both sides of the 
CA-SP1 segment and SP1 removal is 
required for mature CA lattice formation 
47,48. A functional role of p6 and SP2 
removal from NC is at present not clear, 
although SP2 has been shown to help in 
HIV-1 particle release 49. Preventing 
cleavage of NC and p6 does not affect processing upstream but severely reduces infectivity 
50, whereas blocking cleavage of NC and SP2 gave several discrepancies 51,52. The maturation 
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of the virion transforms the non-infectious virion particle into an infection-transmitting 
particle by the initiation of proteolytic processing.  
1.4 Implication of HIV-1 Gag interactions on the virus life cycle 
HIV-1 Gag is the major structural protein of the virus. All the information necessary for the 
assembly of an immature virion is encoded in the Gag polyprotein, which is proved by the 
fact that the expression of Gag in the absence of any other viral protein leads to the 
formation of immature virus-like particles (VLP) 53.The assembly of the virus is driven by 
Gag-Gag and other host cell protein interactions with Gag.  
 
Figure 1.4: The full length precursor Gag Pr55 (Blue) with a schematic of interacting regions in green.  
 
Figure 1.4:  
The PDB accession code for the Gag–host interactions are: MA–PIP2 (2h3q, [28]); CA, N-terminal 
domain (NTD)–cyclophilin A (1m9c, [55]); p6 (YPX (n) L)–ALIX (2r02, [99]) and p6 (PTAP)–TSG101 
(1m4p, [100]). 1 
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Figure 1.5:  
a) Schematic representation of the mature HIV-1 virion, showing the viral glycoprotein 
envelope (Env, which is made of glycoprotein 120 (gp120) and gp41 subunits), as well as the 
Gag polypeptide-derived proteins matrix (MA), capsid (CA) and nucleocapsid (NC). The 
conical viral capsid core is assembled from CA hexamers and pentamers. The capsid core 
harbours the viral RNA genome, which is associated with NC. b) The conical capsid core 
assembles into a fullerene cone, containing hexameric (orange) and pentameric (yellow) CA 
subunits. c) Top view and side view of the hexameric subunits that form the primary capsid 
core of HIV-1 (Protein Data Bank (PDB) identifier: 3GV2). Interactions between the CA 
amino-terminal domain (CANTD; blue) and the CA carboxy-terminal domain (CACTD; red) of
adjacent monomers stabilize the assembled hexamer. d) Structure of two CA monomers of a 
hexamer, illustrating the CANTD–CACTD pocket, which mediates interactions between CA and 
host cell proteins 4. 
Gag-Gag Assembly 
This CA-CA interaction is one of the main drivers of Gag assembly and this capsid layer forms 
a continuous but incomplete hexameric lattice. The CA consists of two domains (CA-NTD 
and CA-CTD) joined by a flexible hinge region54, in the immature Gag forms a lattice 
structure by the interaction of full length Gag via the CA region of subsequent Gag 
molecules.  
This arrangement of the CA domain within the immature virus is very different from the 
mature capsid core. By using cryo-electron microscopy and sub-tomogram averaging, Briggs 
et alia suggested that the the CA-NTD undergoes dramatic rearrangement going from the 
immature to mature particles and would require to form new contacts in the process 55. The 
structural details of the immature capsid are discussed further in chapter 4. 
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The fullerene cone formed by the mature viral core (Fig 1.5b) is a result of the ability of the 
N-terminal CA domain to form two different morphological polymers - pentameric and 
hexameric rings 56. The C-terminal CA domain forms dimers to connect these pentameric 
and hexameric rings into a pseudo threefold axis. 56-59. Mutation of the tryptophan184 and 
methionine185 within the C-terminal CA domain (subsequently referred to as WM Gag) , 
disrupts Gag-Gag interactions, suggesting its key involvement in dimerization 60. The CA 
region is an important region for drug targeting, potential inhibitors have been targeted to 
both the N-terminal and C-terminal domains as well as the flexible hinge region 61. Any 
molecule preventing the formation of these CA-CA interactions will have a major effect on 
the virus assembly and replication. Gag-RNA interaction initiates within the cytoplasm 62. To 
select the viral genomic RNA for packaging, Gag molecules selectively incorporate the un-
spliced viral RNA from a pool of cellular RNA.  
Gag-RNA BInding 
NC plays an important role in formation of Gag-Gag interaction during the immature particle 
formation and recognition of nucleic acid during virus replication. This selection is mediated 
by direct binding of the NC region of Gag to the psi (ψ) packaging sequences on the RNA. As 
there are around 2500-5000 copies of nucleic acid binding proteins within the HIV-1 particle, 
it would suggest that NC would interact with nucleic acid during replication. Recognition of 
the NC by the HIV-1 RNA is carried out by a ~120 nucleotide region present on the RNA, 
located between the 5’ long terminal repeat (LTR) and the gag intiation codon 63. This region 
contains four stem loop structures denoted SL1-SL4, which are all crucial for RNA 
encapsidation 64,65. Among different strains within HIV-1 SL3 is highly conserved and linkage 
of heterologous RNA to SL3 is sufficient to direct their recognition and packaging into virus-
like particle 66. SL3 referred to as psi (ψ) in our studies, has also shown the highest affinity 
for the Gag NC domain, interacting with NC through its two zinc fingers 67 under in vitro 
conditions. Stem loop 2 (SL2) contains the splice donor (SD) stem containing the 5’ splice 
site responsible for generating viral mRNAs and the major packaging signal. Mutational 
studies of SL2 have suggested that stable hairpin within the SL2 sequence favours binding to 
the precursor Gag molecule Pr55 Gag 68. The stem loop 1 (SL1) contains the dimerization 
initiation site (DIS), which is a palandromic sequence mediating RNA-RNA interactions 
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between two RNA strands 69. The SL1 binds specifically to Pr55 Gag and the lower stem of SL1 
has shown to be essential for this binding.  
Upstream from SL1 is an 18 nucleotides (nts) long sequence known as primer binding site 
(PBS). The PBS is complementary to the 3’ terminal 18 nts of the tRNALys3 and is required for 
the tRNA annealing 70. The presence of tRNALys3 serves as the primer tRNA for reverse 
transciptase (RT)-catalysed synthesis of minus strand DNA 71.  
RNA dimerization is an essential step in the virus replication cycle as not only it helps in 
packaging but also affect assembly of the virus 72. HIV-1 packages two copies of RNA 
genome into one particle, even though only one provirus is generated from an infection 
event 72. Frequent recombination occurs during reverse transcription between sequences  
encoded by the two packaged RNAs 73, hence having two RNA copies is proposed to allow 
frequent recombination to occur in order to increase genetic variations 73. Although studies 
Figure 1.6: 
 Illustration of a working model of the HIV-1 5' UTR showing the various stem-loop structures 
important for virus replication. These are the TAR element, the poly(A) hairpin, the U5-PBS 
complex, and stem-loops 1–4 containing the DIS, the major splice donor, the major 
packaging signal, and the gag start codon, respectively. Nucleotides and numbering 
correspond to the HIV-1 HXB2 sequence 2.   
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have shown dimerization of short in vitro-transcribed HIV-1 RNA occurring in the absence of 
Gag, the dimerization efficiency increases in the presence of Gag, moreover under in vivo 
conditions the RNAs are dimeric74. These results suggest that Gag might promote RNA 
dimerization or stabilise the RNA dimers. 74. Although Gag does promote RNA dimerization, 
it does not seem to display any greater preference to the dimerized RNA under in vitro 
conditions 67.   
Within the cytoplasm, it has been proposed that Gag forms low-order Gag-Gag and Gag-
RNA oligomers, which act as nucleation points for further Gag assembly 75. Although since 
this study was exclusively focused on cytosolic Gag oligomerization, it would be difficult to 
show that the lower order Gag oligomers become initiation sites for higher order assembly. 
The MA domain containing N-terminal basic residues which are associated with membrane 
binding of the MA domain can also bind to the RNA in vitro 76,77, but this interaction is still to 
be observed in vivo. Interestingly, cellular RNAs have been shown to be packaged in the 
absence of a ψ sequence, suggesting Gag can interact with RNA in a ψ independent manner 
78. Going from a low-order oligomer in the cytoplasm to a higher-order multimers on the 
plasma membrane, and then maturing into NC and other domains after proteolytic 
processing, Gag undergoes numerous rearrangements 62.  
During these rearrangements, it has been suggested that the sequence specificity of Gag-
RNA binding, changes in order to facilitate genome packaging. These changes have been 
suggested by using crosslinking-immunoprecipitation (CLIP) sequencing79. In the studies it 
was shown that Gag soecificity changes from a GU-rich sequences within the cellular mRNA 
in the cytosol to the A-rich mRNA sequence on the plasma membrane. Although complete 
understanding of this change in Gag-RNA interaction and its implications are still not clear.  
This change is suggested to be a direct result of the dramatic increase in local NC 
concentration, which causes the formation of a pseudo-2D curved array changing the 
accessibility of the zinc fingers and basic residues present within the NC domain 79.  But the 
energy systems that drive the change in Gag-RNA sequence binding during such an 
interaction still remain unanswered. We have tried to address some of these questions with 
our in vitro recombinant Gag production system developed in Chapter 3. Upon forming 
higher-order oligomers at the plasma membrane, Gag specifically links with cholesterol-
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enriched micro-domains known as rafts. Even though the N-terminal Gag mediates raft 
binding, the interaction is greatly enhanced by Gag-Gag interaction domains. Disruption of 
these rafts, leads to a significant decrease in viral infectivity 80 suggesting the Gag–raft 
interaction is an essential step in virus maturation. 
Membrane interaction 
The myristoylated N-terminal MA in precursor Gag is essential for the targeting and 
assembly of Gag at the plasma membrane. MA also binds to nucleic acids through a 
phosphatidylinositol-4, 5 biphosphate (PIP2)-dependent mechanism, which prevents binding 
of the MA to other lipid membranes 76,81. Furthermore, it has been shown that Gag adopts a 
compact bent conformation in solution and remains in a lower order oligomeric state. With 
the addition of RNA, Gag assembles into very small (~25nm size) 82VLP like structures and 
the addition of both inositol phosphatase (IP) and nucleic acid causes it to form an extended 
rod-shaped form 83,84. A short stretch of hydrophobic amino acids next to the myristoylation 
site is in part responsible for interaction between the lipid membrane and the Gag protein. 
The C-terminus of these hydrophobic amino acids binds to the lipid bilayer of the plasma 
membrane1. Hence the MA domain plays an important role in trafficking Gag to the plasma 
membrane for budding of the virus. MA interacts with cytoplasmic tail of a subunit of the 
envelope protein complex known as glycoprotein 41 (gp41) and the transmembrane portion 
of envelope protein to facilitate integration of the envelope protein in the virion 85,86.  
 
Gag Interaction with host cell factors 
Gag is also responsible for packaging and interacting with various host cell factors that 
influence the virus life cycle. Lysyl-tRNA synthetase (LysRS) and tRNALys3 which are packaged 
into the virion by interacting with precursor Gag and gp160, and initiate reverse 
transcription in the host cell. Glyceraldehyde 3-phosphate dehydrogenase which is involved 
in various host cell processes such as glycolysis nuclear RNA export and DNA repair 
competes with the LysRS/tRNALys3 complex to bind to Gag and in doing so reduces LysRS and 
tRNALys3 packaging efficiency 87.  The NC domain of Gag interacts with APOBEC3G, which is a 
deaminase-editing enzyme that displays anti-retroviral activity 88. This anti-retroviral activity 
of APOBEC3G is counteracted by the virus-encoded accessory protein called virion infectivity 
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factor (Vif) 89. APOBEC3G needs to be encapsidated within the virus to be effective as an 
anti-retroviral, this encapsidation occurs through its interaction with Gag protein 90. This 
binding of APOBEC3G and abundant Gag within the virus has also been hypothesised to help 
deplete APOBEC3G levels by degradation when it is complexed with Gag 88.  
A cellular ATP-binding protein ABCE1 (also known as HP68 or RNase L inhibitor) is an 
essential protein required for capsid assembly.  In primate cells, ABCE1 was suggested to 
associate with NC domain of Gag and any other domain of Gag prove to be dispensable for 
this Gag-ABCE1 interaction 91. Another study conducted with Gag mutants in which the NC 
domain was replaced by a leucine zipper, exhibited that in fact ABCE1 does not bind to NC 
directly but the dimerization mediated by NC causes an ABCE1 binding domain to be 
exposed within the Gag molecule 92. 
During the budding process curvature of the membrane is mediated by Gag-Gag 
interactions along with other cellular proteins and membrane lipids 93,94. In order to detach 
from the membranous neck connecting the virion to plasma membrane of the host cell, HIV-
1 and numerous other enveloped viruses hijack the host cell machinery known as ESCRT 
complexes. In the host cell, ESCRT complexes and associated proteins such as Alix play 
crucial roles in membrane fission events such as MVB formation and cytokinesis 95. 
Mammalian ESCRT-I is composed of five subunits TSG101, Vps28, Vps37, MVB12 and UBAP1 
96-98. TSG101 is directly involved in life cycle of HIV-1 by direct interaction through its UEV 
domain with the PTAP sequence present within the p6 domain of HIV-1 Gag. TSG101 was 
identified as a p6-interacting protein by yeast two-hybrid analysis 99, any mutations in the 
PTAP motif disrupt this interaction and causes a budding defect of the virus. Structural 
studies have shown the PTAP peptide binds UEV in a groove above the inactive enzymatic 
site 39,100.  
Even though HIV-1 relies essentially on TSG101 interaction with the PTAP motif of Gag, it 
has been shown that overexpression of Alix rescues HIV-1 budding in PTAP Gag mutants 
101.Alix is a cytoplasmic protein which was first identified as an interactor of ALG-2 protein 
and may help in regulating apoptosis 102. Within Alix, the Bro1 domain interacts with NC 
region of Gag, V domain interacts with p6 domain of Gag and the proline rich domain with 
cellular factors such as TSG101 103. Bro1 domain consists of a conserved site which interacts 
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with ESCRT-III subunit CHMP4 and the NC region of Gag, whereas the V domain binds to the 
viral YPDL motif present on the late domain of HIV-1 Gag. The interaction between NC 
domain of Gag and Bro1 domain of Alix is shown to be nucleic acid dependent 104. 
Majority of in vitro biochemical and biophysical studies done on recombinant HIV-1 Gag 
have made use of the p6 deleted mutant. Therefore it still remains to be determined 
whether p6 has any other major implications during the assembly and maturation process 
of the HIV virus biochemically. 
1.5 Current treatments 
 
Figure 1. 7: 
 Drugs (Pink box) targeting various stages of HIV-1 Life cycle. Even with recent 
advancements, there has not been any compounds or drugs targeting the Gag protein. 
Presently there are no permanent cures or vaccines against AIDS, the only options consist of 
long-term viral replication suppression of HIV-1 using anti-retroviral drugs. In HIV-1 infected 
patients there is a high degree of genetic diversity within the virus population which is 
caused by a rapid viral replication rate and a highly error prone viral polymerase, unless the 
replication is suppressed by antiretrovirals105. Different strategies have recently become 
available for targeting different stages of the HIV-1 life cycle; such as fusion inhibitors, viral 
entry and integration inhibitors 106,107. Increases of viral load in a patient receiving anti-
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retroviral drugs often leads to the use of salvage or rescue therapy, which involves multi-
drug combinations for treatment as the preferred treatment. This increase in viral load is 
largely due to development of resistance against the anti-retroviral drugs by the virus, which 
occurs either due to non-compliance by the drug user or mutations within the virus 
population leading to resistance.  
Major research advances have led to licensing of more than 30 different anti-HIV active 
compounds and combined anti-retroviral therapy (c-ART), which has reduced mortality 
significantly. Although this therapy works well in keeping the virus population in check, the 
long-term use of such pharmacological treatments have been attributed to certain side 
effects such as renal insufficiency and lower bone density108. Any interruption in the therapy 
has also been shown to cause viremia and recovery of systemic infection 109. This is due to 
the life-long persistence of the virus in reservoirs of latently infected cells, wherein the 
integrated provirus is not affected by c-ART that only targets active replicating viruses.  
Promising new strategies for treatment such as HDAC inhibitors and activation of 
transcription factors have shown promising results 110, but more advances need to be made 
in order to address their own side effects such as broad cell activation and off-target effects 
they might induce.  
The continuous evolution of drug resistance is an ongoing challenge. In order to maintain 
the efficacy of treatments such as ART, we need to continue improving drugs and discover 
new novel drug targets. Gag is an ideal target for drug development as it represents multiple 
ranges of distinct targets during different stages of viral replication cycle. Compounds 
currently targeting the CA region or inhibiting Gag maturation, work efficiently even at low 
concentrations. Elucidating the structure of full length Gag, thus becomes pivotal as it will 
not only provide us with opportunities for drug development but also help us in 
understanding the molecular mechanisms underlying HIV-1 replication.  
1.6 Conclusion and Aims 
 
Lack of sufficient quantities of recombinant Gag, have made it quite challenging to make 
progress in this direction. With our ability to produce full length recombinant Gag in 
sufficient purity and quantity, makes Gag as a promising candidate for drug development. 
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Using the purified Gag, we can closely monitor the various maturation stages of the 
precursor protein as well as the implication of cleavage on the intricate Gag-RNA 
interaction. A better understanding of these processes can lead to discovery of new motifs 
exposed during various stages of maturation, which can potentially become new drug 
targets. 
The projects in this study were conducted in order to tackle some of the issues surrounding 
HIV-1 Gag. The first chapter describes the procedure to express and purify recombinant full 
length HIV-1 Gag from E.coli. The second chapter involves using the recombinant protein to 
look at the thermodynamics of the evolving relationship between the HIV-1 structural 
protein Gag and its interaction with RNA, which helps in packaging of the genome inside a 
mature infectious virus. In the third chapter while we did set out to obtain structural 
information of Gag protein, we only could obtain the right conditions that could be further 














Chapter 2: Expression and purification of soluble recombinant full 
length HIV-1 Gag protein (Pr55) in Escherichia coli 
In order to successfully use HIV-1 Gag as a candidate for drug target, we successfully cloned 
the Gag expressing gene from HIV clone pNL4.3 into a bacterial protein expression plasmid. 
The following chapter describes our published protocol which demonstrates the successful 
expression and purification of soluble recombinant full length HIV-1 Gag (Pr55Gag) using a 
heterologous bacterial expression system, incorporating a C-terminal hexa-histidine tag to 
facilitate affinity purification tag using an immobilized metal ion affinity column.  The 
expression plasmid was been designed without the need for bulky protein solubility and/or 
affinity purification tags, as they would likely interfere with the Gag assembly process during 
virus maturation. 
2.1.  Publications relating to this chapter 
William J. McKinstry, Marcel Hijnen, Hanumant S. Tanwar, Lindsay G. Sparrow, Sureshbabu 
Nagarajan, Son T. Pham, Johnson Mak, Expression and purification of soluble recombinant 
full length HIV-1 Pr55Gag protein in Escherichia coli, Protein Expression and Purification, 
Volume 100, August 2014, Pages 10-18, ISSN 1046-5928. 
2.2. Abstract 
The HIV-1 Gag precursor protein, Pr55Gag, is a multi-domain polyprotein that drives HIV-1 
assembly. The morphological features of HIV-1 suggested Pr55Gag assumes a variety of 
different conformations during virion assembly and maturation, yet structural 
determination of HIV-1 Pr55Gag has not been possible due to an inability to express and to 
isolate large amounts of full-length recombinant Pr55Gag for biophysical and biochemical 
analyses. This challenge is further complicated by HIV-1 Gag’s natural propensity to 
multimerize for the formation of viral particle (with ∼2500 Gag molecules per virion), and 
this has led Pr55Gag to aggregate and be expressed as inclusion bodies in a number of in 
vitro protein expression systems. This study reported the production of a recombinant form 
of HIV-1 Pr55Gag using a bacterial heterologous expression system. Recombinant HIV-1 
Pr55Gag was expressed with a C-terminal His×6 tag, and purified using a combination of 
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immobilized metal affinity chromatography and size exclusion chromatography. This 
procedure resulted in the production of milligram quantities of high purity HIV-1 
Pr55Gag that has a mobility that resembles a trimer in solution using size exclusion 
chromatography analysis. The high quantity and purity of the full length HIV Gag will be 
suitable for structural and functional studies to further understand the process of viral 
assembly, maturation and the development of inhibitors to interfere with the process. 
2.3. Introduction  
The HIV-1 Gag precursor protein, Pr55Gag, is the major structural protein that drives the 
formation of HIV-1 particles. Both Pr55Gag of HIV-1 and retroviral Gag are critical as these 
virus assembly machineries are responsible: to select viral genomic RNA for packaging; to 
direct the protein to the inner plasma membrane for oligomerization; and to hijack host 
ESCRT proteins to facilitate virion particle egress100,111, through different domains within the 
polyprotein. Owing to its importance in HIV-1 function, understanding the biochemical and 
biophysical property of HIV-1 Pr55Gag is paramount to HIV-1 biology. However, despite HIV-1 
being discovered nearly 3 decades ago6,112, large quantities of recombinant full-length 
Pr55Gag proteins are still unavailable for biochemical and biophysical analyses. Perhaps the 
only exception is work from Carlson and Hurley113 in which, recombinant Pr55Gag was 
generated by fusing the C-terminus of HIV-1 protein with a 42 kDa expression/purification 
tag, maltose-binding protein (MBP). Alternatively, most laboratories prepare HIV-1 Gag 
protein by deleting the last 52 amino acids from the C-terminus (p6Late domain) to stabilize 
the expression and the purification of HIV-1 Gag 82,114. It is likely that the C-terminus fusion 
of MBP has helped to stabilize HIV-1 Pr55Gag during expression and purification. The C-
terminus p6 late domain is important for recruitment of host cell factors ESCRT 115,116and 
recombinant Gag proteins lacking p6Late domain are not ideal for Pr55Gag characterization. 
Pr55Gag relies on its poly-protein domains to facilitate particle formation and virion release. 
Briefly, several thousand copies of the Gag poly-protein assemble at cholesterol- and 
sphingolipid-rich micro-domains on the plasma membrane of virus producing cells53,117-120, 
where Pr55Gag organize themselves into a lattice-like structure and form spherical budding 
virus-like particles. During or immediately after budding, Pr55Gag undergoes stepwise 
sequentially proteolytic processing by HIV protease, which resulted in a series of 
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conformational rearrangement events to form mature infectious virus particle121-123. Pr55Gag 
consists of four major protein components (from N-terminus to C-terminus) known as 
matrix (MA, p17MA), capsid (CA, p24CA), nucleocapsid (NC, p7NC), and the p6Late Domain, 
while short linker peptides, SP1 and SP2 flank either side of the NC domain. Importantly, 
these different domains contribute to the oligomerization of the mature proteins and the 
precursor Pr55Gag. 
From the N-terminus of Pr55Gag, MA is a highly basic protein domain (Gag1–132) with a core 
molecular weight of ∼17 kDa, and it exists in the context of Pr55Gag precursor, p39MA-CA-
SP1 intermediate and p17MA mature protein. The myristylation of Gly2 in MA targets the Gag 
protein to the plasma membrane111,124, and mutation of this glycine myristylation site 
prevents virus budding and leads to accumulation of Gag within the host cell125. The 
structure of MA has been determined by both X-ray crystallography and NMR, and 
comprises 5 alpha helices and a three strand mixed beta sheet126,127 which forms a trimer in 
the virion shell in the mature HIV-1 particle. It is presumed that the MA trimerizes in the 
context of Pr55Gag precursor protein during HIV-1 assembly 127. 
The second major domain in Pr55Gag is CA (24 kDa), and it forms a fullerene shell 
surrounding the viral RNA genome and core associated proteins in mature viruses. CA is 
comprised of two sub-domains, referred to as the NTD (N-terminal domain) and CTD (C-
terminal domain) connected by a flexible linker. The NTD is comprised of seven α-helices 
and an N-terminal β-hairpin loop, with biochemical and genetic analyses demonstrating this 
domain is important for mature capsid assembly128.. The CTD is roughly spherical, consisting 
of four α-helices and a 310 helix, and forms dimers in solution 129. The linker region joining 
both NTD and CTD is also important for capsid assembly and viral infectivity130. Within the 
mature viral capsid core, CA assembles into both hexamer and pentamer structures56,131, 
and recent cryo-electron microscopy identified cone-shaped structures comprising 12 
pentamers with either 216 or 186 hexamers132, which is in agreement with previous 
estimation/model of the structure of the fullerene cone capsid core 13,133.  While it is almost 
certain that the arrangement of CA–CA interactions during HIV assembly are different from 
the CA–CA interactions in the mature virion core, yet our current understanding of CA–CA 
structure during assembly is extremely limited. 
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The third domain, nucleocapsid (NC) is a highly basic protein (∼7 kDa) and contains two 
CCHC-type zinc finger motifs 134. The zing finger motifs enable Gag to recruit genomic RNA 
molecules to newly forming virions, and to assist in Gag–Gag interactions during virus-like 
particle formation135,136. The ability of NC to interact with genomic RNA is critical for the 
oligomerization and eventual formation of virus like particles in vitro. However, the precise 
mechanism on how NC mediated this process remains unexamined due to the lack of full 
length Pr55Gag for biochemical and biophysical analysis. 
The C-terminal domain, p6Late contains N- and C-terminal helical domains connected by a 
flexible hinge region137, containing two “late domain” motifs (PTAP and LYPXnL) that bind 
and recruit host cell ESCRT proteins TSG101 and Alix that are essential for virus budding, and 
the LXSLFG motif that is required for the incorporation of the viral accessory protein Vpr 
into virus particles138,139. Despite the identification of these important motifs and amino 
acids within HIV p6Late domain, in the absence of soluble Pr55Gag, it is currently unknown 
how any of these interactions would affect the folding Pr55Gag and the dynamics of Gag 
oligomerization during HIV assembly. 
Previously, researchers had expressed individual MA, CA, and NC domains and intermediate 
forms of Gag, including mutations that result in the formation of stable monomers 
in Escherichia coli for structural and functional studies82,84,114,140. This is the first reported 
use of a bacterial heterologous protein expression system to produce soluble recombinant 
wild-type, full length, HIV-1 Pr55Gag protein, without the need for solubility tags that can be 







2.4. Materials and methods 
2.4.1. Bacterial strains and media 
All transformation steps were carried out using the E. coli strains DH5α and BL21(DE3)pLysS 
using standard heat shock of RbCl2 competent cells. For the production of plasmid DNA in 
DH5α cells and the production of recombinant protein in BL21(DE3)pLysS, cells were 
cultured in LB media [1% (w/v) peptone, 0.5% (w/v) yeast extract, and 0.5% NaCl]. The 
media was supplemented with the antibiotics kanamycin (50 μg/mL; DH5α) and both 
kanamycin and chloramphenicol (35 μg/mL; BL21(DE3)pLysS). 
2.4.2. Plasmid construction 
 
The HIV molecular clone pNL4.3141 served as template DNA for amplifying the full length 
wild-type HIV-1 Pr55Gag gene. The target gene was amplified using oligonucleotide primers 
designed according to the full length gene sequence of HIV-1 Pr55Gag and the restriction 
sites for NcoI and XhoI were included at the ends of the primers for ligation dependent 
cloning into a modified pET28a protein expression vector. The forward primers were 5ʹ-
AACCATGGGTGCGAGAGCGTCGGTA-3ʹ and the reverse primer was 5ʹ-
AAACTCGAGTTGTGACGAGGGGTCGCT-3ʹ, with the underline regions representing the 
recognitions sites for the restriction endonucleases NcoI and XhoI, respectively. This vector 
is a derivative of the pET28a in which the N-terminal His×6 tag and protease cleavage site 
were removed and replaced with a C-terminal His×6 tag to facilitate protein purification 
using IMAC. The total PCR reaction volume was 100 μL including 10 μL of the template DNA, 
and 2 μL of Vent DNA polymerase (New England Biolabs). PCR conditions were as follows: 
initial denaturation 95 °C for 5 min, then 35 cycles of denaturation at 95 °C for 45 s, primer 
annealing at 58 °C for 45 s, followed by primer extension at 72 °C for 90 s. A final extension 
step proceeded at 72 °C for 7 min. The size of PCR product was confirmed by 
electrophoresis on a 1.2% agarose gel, treated with SYBRSafe DNA stain and visualized by 
UV illumination. The remaining amplified DNA was column purified (Qiagen). The purified 
HIV-1 Pr55Gag coding DNA sequence was excised with NcoI and XhoI at 37 °C for 60 min, 
column purified and then ligated using T4 DNA ligase into the linearized modified pET28a 
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vector, that have previously been cleaved with NcoI and XhoI. The Pr55Gag–pET28a 
expression plasmid was verified by DNA sequencing. 
2.4.3. Analytical protein expression studies 
Small scale recombinant protein expression studies were performed by inoculating a single 
colony into 5 mL LB media containing antibiotics overnight at 37 °C, with shaking at 
160 rpm. The overnight culture was used to inoculate 5 mL fresh LB media containing 
antibiotics at a starting OD600 nm 0.1 and the culture was grown at 37 °C, 160 rpm, until an 
OD600 nm of 0.8 was reached. The expression of HIV-1 Pr55Gag was induced by the addition of 
0.8 mM isopropyl-β-d-thiogalactopyranoside (IPTG, GoldBio) at 28 °C, and protein 
expression monitored over an 18 h period by the collection of 500 μL culture aliquots 
at T = 0, 1, 4, and 18 h post induction and cells harvested by centrifugation at 14,000 rpm for 
5 min. The bacterial cell pellets were solubilized in Cell Lytic B (Sigma) for analysis by SDS–
PAGE and Western blotting. 
2.4.4. Large scale protein production 
Large scale recombinant protein production was performed by inoculating a single colony 
into 25 mL LB media containing antibiotics, and cultured at 37 °C, overnight with shaking at 
200 rpm. The overnight culture was used to inoculate 1.0 L LB media containing antibiotics 
in a 2.5 L baffled glass erlenmeyer flask. The culture was grown at 28 °C, 200 rpm, until an 
OD600 nm of approximately 0.6 was reached. Protein expression was induced with the 
addition of 0.8 mM IPTG, and the cells grown for a further 4 h at 28 °C. Cells were harvested 
by centrifugation (6000 rpm, 4 °C, 15 min), and cell pellets stored at −80 °C. Cell pellets from 
the equivalent of 6.0 L of cultures were resuspended in 100 mL ice cold Cellytic B (Sigma) 
containing 500 units of Benzonase (Merck) and 1 EDTA-free protease inhibitor tablet 
(Roche). Following re-suspension and solubilization, DNA was sheared by repeated passage 
through a 23 gauge needle. The lysate was centrifuged to remove insoluble material 
(14,000 rpm, 15 min, 4 °C), and a 4× stock of 0.2 M TRIS–HCl pH 8.0, 4.0 M NaCl, 40 mM β-
mercaptoethanol, 10 mM dithiothreitol, 100 mM imidazole, 4% (w/v) Tween-20 added to 
the lysate to give a final concentration of 50 mM TRIS–HCl pH 8.0, 1.0 M NaCl, 10 mM β-
mercaptoethanol, 2.5 mM dithiothreitol, 25 mM imidazole, 1% (w/v) Tween-20. The lysate 
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was filtered through a 0.45 μm syringe filter and loaded onto a 5 mL HisTRAP fast flow 
cartridge (GE Healthcare) that had previously been equilibrated with 50 mM TRIS–HCl pH 
8.0, 1.0 M NaCl, 10 mM β-mercaptoethanol, 2.5 mM dithiothreitol, 25 mM imidazole, 1% 
(w/v) Tween-20, 10% (v/v) glycerol. The column was washed with equilibration buffer and 
bound proteins eluted with a 0–1000 mM imidazole gradient in equilibration buffer. 
Fractions containing Pr55Gag were pooled and concentrated using a centrifugal Ultra-15, 
10,000 molecular weight cut-off membrane (Millipore). The concentrated protein was then 
fractionated by gel filtration chromatography using a Superdex 200 26/60 column (GE 
Healthcare) previously equilibrated in 50 mM TRIS–HCl pH 8.0/1.0 M NaCl. Peak fractions 
from this column containing Pr55Gag were pooled and concentrated to 1–2 mg/mL, and snap 
frozen in liquid nitrogen before storage at −80 °C. 
2.4.5. SDS–polyacrylamide gel electrophoresis and Western blotting 
Analytical Pr55Gag protein expression studies and the purification of recombinant 
Pr55Gag were monitored by both SDS–PAGE and Western blotting under reducing conditions 
on a 4–12% Bis–Tris NuPAGE gel (Life Technologies) using MES electrophoresis. Samples 
were incubated with SDS sample buffer containing 10 mM dithrothreitol and heated to 
95 °C for 5 min prior to loading onto gels. Protein gels were stained with Coomassie Brilliant 
Blue. Replicate gels were transferred onto a nitrocellulose membrane for Western blotting. 
The membrane was blocked in phosphate-buffered saline containing 5% (w/v) skim milk 
powder and 0.1% Tween-20 (v/v) for 30 min, followed by incubation with an anti-His 
monoclonal antibody-HRP conjugate (Sigma) to detect His tagged proteins; or an anti-HIV-1 
capsid monoclonal antibody (Clone 183-H12-5c; NIH AIDS Reagent program) followed by a 
secondary rabbit anti-mouse IgG-HRP conjugate (Dako) to detect Gag proteins. The 
membranes were washed several times with phosphate-buffered saline containing 0.1% 
Tween-20 (v/v) before being developed using either 3,3ʹ,5,5ʹ-tetramethylbenzidine or 
chemiluminescence substrates. 
2.4.6. Peptide mass fingerprinting 
Proteins were prepared by in-gel trypsinization for analysis by matrix-assisted laser 
desorption/ionization and time of flight mass spectrometry (MALDI-TOF-MS). Briefly, the 
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10 μg of purified Pr55Gag was electrophoresed on a 4–12% gradient NuPAGE gel, using the 
MES buffer system; stained with Coomassie brilliant blue R250, destaining with 
methanol/acetic acid, the target protein band was excised from the gel, minced and then 
digested with trypsin at 37 °C for 16 h. The trypsinized peptides were extracted with 60% 
acetonitrile/0.1% trifluroacetic acid, and a 1.0 μL aliquot pipetted onto a MALDI stage, and 
an equal volume of α-hydroxy cyanocinnamic acid added to the peptide mix. Mass 
fingerprinting was performed using by MALDI-TOF-MS (ultrafleXtreme, Bruker). The 
resultant peptides generated were identified by searching SWISS-PROT and NCBI-nr 
databases using the Mascot 2.0 search engine with fragment mass tolerance of +/− 
0.5 daltons and max missed cleavages of one. 
2.4.7. Electrospray mass spectrometry 
Purified HIV-1 Pr55Gag was desalted by reverse-phase HPLC using a C18 Jupiter column 
(Phenomenex), and the protein eluted directly onto a microTOF-QII electrospray ionization 
mass spectrometer (Bruker) using a gradient of acetonitrile containing 0.1% formic acid. The 
mass of the resulting peaks were determined by entropy-based deconvolution algorithms. 
2.4.8. Preparation of virus-like particles and electron microscopy analysis 
HIV-1 Pr55Gag at a protein concentration of 2.0 mg/mL in 20 mM TRIS pH 7.4 containing 
1.0 M NaCl and 10 mM dithiothreitol was mixed with yeast t-RNA at a nucleic acid to protein 
ratio of 4% (w/w) prior to dialysis against 20 mM TRIS pH 7.4 containing 150 mM NaCl and 
10 mM dithiothreitol overnight at 4 °C. 
Transmission electron microscopy (TEM) was performed on negatively stained VLPs. Briefly, 
8 μL VLP suspension was transferred to a formvar/carbon coated grid (Proscitech, Australia) 
for 5 min. After binding, the grid was washed twice with PBS followed by staining with 2% 
uranyl acetate for 5 min. Excess stain was soaked off by touching the grid to a filter paper. 
After staining the grid was air dried. TEM was performed on using a JEOL 1400 electron 
microscope (JEOL, Japan) with a magnification range of 15,000–50,000. Images were taken 




2.5.1. Construction of expression plasmid coding HIV-1 Pr55Gag  
The full length coding sequence of the HIV-1 Pr55Gag (1500 bp; Fig 2.1b) was amplified from 
pNL4.3, and cloned into a modified pET28a vector containing a C-terminal His×6 tag to 
generate pET28a–Pr55Gag (Fig 2.1c). Further characterization using specific restriction 
endonuclease digests and DNA sequencing demonstrated that the target amplified gene 
was inserted into the correct open reading frame of the vector. The resultant expression 
construct produced a fusion protein comprising full length HIV-1 Pr55Gag and a LEHHHHHH 





Figure 2.1 : 
HIV-1 Pr55Gag. (A) Schematic representation of the HIV-1 genome organization, detailing the 
domain organization of Gag. (B) Full length gene sequence of HIV-1 Pr55Gag pNL4.3. (C) 
Schematic diagram of HIV-1 Pr55Gag-modified pET28a expression plasmid. The recombinant 
gene encoding Pr55Gagrepresenting the full length HIV-1 Gag, containing the MA, CA, NC, 
and p6 domains was cloned into a modified pET28a (+) vector and expressed in Escherichia 
coli BL21(DE3)pLysS under the control of the strong bacteriophage T7 promotor. (D) Full 
length amino acid sequence of HIV-1 Pr55Gag. The domains are color coded accordingly; 
matrix – orange, capsid – red, nucleocapsid – blue, and p6 – green, SP1 – purple, SP2 – pink, 
vector associated C-terminal His tag – black. 
2.5.2. Expression and purification of recombinant Pr55Gag 
pET28a–Pr55Gag was transformed into BL21(DE3)pLysS for recombinant protein production. 
Protein expression was induced with the addition of 0.8 mM IPTG at either 18 °C or 28 °C, 
and expression analysed at 1, 4, and 18 h post induction by SDS–PAGE and Western blotting. 
Recombinant HIV-1 Pr55Gag was only observed for the 28 °C expression study at both 4 and 
18 h time points (Fig. 2.2). A Coomassie Blue stained band was observed migrating ∼57 kDa 
which corresponded to that expected for the His-tagged HIV-1 Pr55Gag, with the identity of 
this band confirmed by Western blotting using the anti-His monoclonal antibody-HRP 
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conjugate. Chemical solubilization of the bacterial cells using a proprietary formulation of 
zwitterionic detergents in 40 mM TRIS–HCl buffer pH 8.0 suggested that HIV-1 Pr55Gag was 
soluble and not expressed as inclusion bodies in the analytical protein expression 
experiments. 
 
Figure 2.2 :  
Analytical recombinant HIV-1 Pr55Gag protein expression. (A) SDS–PAGE analysis of bacterial 
lysates at 0, 1, 4, and 18 h post-induction with 0.8 mM IPTG at 28 °C. (B) Western analysis of 
duplicate gel transferred onto nitrocellulose and probed with a mouse monoclonal anti-His-
HRP conjugate antibody 
Large scale protein expression and purification was undertaken using 2.5 L baffled glass 
erlenmeyer flasks containing 1.0 L LB medium. Recombinant HIV-1 Pr55Gag expression was 
induced at 28 °C with 0.8 mM IPTG and cells harvested 4 h post induction. HIV-1 Pr55Gag was 
purified using a combination of immobilized nickel affinity chromatography and size 
exclusion chromatography under non-denaturing conditions in the presence of 1.0 M NaCl 
to prevent protein aggregation and precipitation. Longer induction times during protein 
expression resulted in increased levels of higher molecular weight soluble aggregates. HIV-1 
Pr55Gag eluted from the Nickel column with 160 mM imidazole, was concentrated and was 
further fractionated on a Highload Superdex 200 column where it migrated with an 
apparent molecular weight of ∼150 kDa consistent with behaving as a trimer in solution 
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(Fig. 2.3a). Two small higher molecular weight peaks were observed migrating in the void 
volume and ∼400 kDa, but these were not related to HIV-1 Pr55Gagas assessed by SDS–
PAGE. The peak HIV-1 Pr55Gag fractions were >95% pure as assessed by SDS PAGE (Fig. 2.3b). 
These fractions were pooled and concentrated to 1.0 mg/mL before snap freezing. We 
reproducibly obtained 6 mg of purified HIV-1 Pr55Gag from 6 × 1.0 L cultures in 2.5 L shake 
flasks with a yield of 1.0 mg/L of culture. The purified HIV-1 Pr55Gag could be concentrated 
to between 1 and 2 mg/mL in the high salt buffer without protein precipitation or 
aggregation occurring. Repeated cycles of freeze thawing did not appear to result in the 
formation of protein aggregates or precipitates as assessed by high speed centrifugation 
and SDS PAGE electrophoresis. 
 
Figure 2.3:  
Size exclusion chromatography of HIV-1 Pr55Gag. (A) Analysis of IMAC purified HIV-1 
Pr55Gag on a Superdex 200 16/60 gel filtration column equilibrated in 50 mM TRIS–HCl pH 
8.0 containing 1.0 M NaCl. A major peak with an apparent molecular weight of ca. ~150kDa 
corresponding to trimeric HIV-1 Pr55Gagwas observed. The elution volumes of the gel 
filtration standards used for calibration are indicated along with their molecular weights (in 
kDa). (B) SDS–PAGE analysis of the main peak fractions eluting with a molecular mass of 57 
kDa on a 4–12% Bis–Tris NuPAGE gradient gel under reducing conditions in MES 
electrophoresis running buffer and Coomassie Brilliant Blue staining. (C) Western blot 
analysis of pooled HIV-1 Pr55Gag fractions post size exclusion chromatography probed with 
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an anti-His-horseraddish peroxidase monoclonal antibody conjugate. A recombinant C-
terminal His-tagged tannase was included as a positive control. (D) Western blot analysis of 
pooled HIV-1 Pr55Gag fractions post size exclusion chromatography probed with an anti-Gag 
monoclonal antibody, followed by a polyclonal rabbit anti-mouse IgG-horseraddish 
peroxidase conjugate. A recombinant HIV capsid protein (p24) was included as a positive 
control. 
Western blotting using an anti-Hisx6 monoclonal antibody confirmed that the ∼55 kDa 
protein purified by a combination of IMAC and size exclusion chromatography contained a 
His-tag. A recombinant bacterial tannase containing a C-terminal His×6 tag served as a 
positive control (Fig. 2.3c). Furthermore, Western blotting of the purified HIV-1 Pr55Gag using 
an anti-HIV capsid monoclonal antibody (Clone 183-H12-5c) confirmed the ∼55 kDa band 
was immuno-reactive for Gag. A recombinant HIV capsid protein p24 was included as a 
positive control (Fig. 2.3d). 
Subsequently, the partial peptide sequence of HIV-1 Pr55Gag was confirmed by MALDI-TOF 
MS analysis. Small peptides were generated by trypsin digestion and were analyzed using 
MALDI-TOF-TOF (Fig. 2.4a). Our results identified 17 peptides that were identical to HIV-1 
Pr55Gag in the MASCOT database, representing 48% sequence coverage of query. A mass of 
56748.08 daltons was obtained for the purified HIV-1 Pr55Gag by ESI mass spectrometry 
which was 135 daltons less than the expected mass of 56883.80 (Fig. 2.4b). The resultant 
difference could be attributed to the loss of a histidine residue from the C-terminal His-tag. 
A second m/z peak at 11035.01 Da with a similar intensity to the main HIV-1 Pr55Gag peak 
did not correspond with any protein bands migrating on SDS–PAGE. Analysis of the HIV-1 
Pr55Gag sequence using the web based proteomics tool (http://web.expasy.org/cgi-
bin/findpept) identified four peptides for unspecific cleavages that are very close in mass to 







Figure 2.4:  
Mass spectrometry analysis of HIV-1 Pr55Gag. (A) Peptide mass fingerprinting of HIV-1 
Pr55Gag based on MALDI-TOF-MS. The peaks represented the individual trypsinized peptide 
fractions and marked by the corresponding m/z values (molecular weight). The peak height 
is peptide signal intensity. (B) Electrospray ionization mass spectroscopy of HIV-1 Pr55Gag. 
Potential un-specified cleaved HIV-1 Pr55Gag peptides attributed to the second m/z peak at 
11035.01 kDa identified using the web based proteomic tool (http://web/expasy.org/cgi-
bin/findapept). 
2.5.3. Functional activity of recombinant Pr55Gag 
The in vitro assembly of recombinant HIV-1 Gag lacking the p6 domain has the intrinsic 
ability to spontaneously multimerize and form spherical virus-like particles in the presence 
of nucleic acids 82. We showed that purified recombinant HIV-1 Pr55Gag that had been stored 
at −80 °C in the presence of 20 mM TRIS pH 8.0 containing 1.0 M NaCl and 1 mM DTT and t-
RNA, when dialysed against the same buffer containing only 100 mM NaCl at 4 °C, 
assembled into spherical particles with a diameter of 20 nm that were observed by 
transmission electron microscopy (Fig. 2.5). These particles are similar in morphology to 
those obtained for recombinant HIV-1 Gag that lacked the p6 domain, albeit 10–20 nm 





 Electron micrographic analysis of recombinant HIV-1 Pr55Gag VLPs. (A) and (B) negative 
stained transmission electron micrographs of recombinant HIV-1 Pr55Gag VLP. (B) TEM 



















Previous reports have expressed individual functional domains of Gag, or truncated Gag that 
has one or more domains deleted82-84,114,140,142 . In this report, we describe the expression 
and purification of soluble full length wild-type HIV-1 Pr55Gag using a heterologous bacterial 
expression system. Our PAGE and chromatographic analyses have shown that it is possible 
to generate large amount of recombinant soluble HIV Pr55Gag protein for subsequent 
biochemical and biophysical analysis. Our mass spectrometry data have confirmed the 
identity of our soluble recombinant protein. While the mobility profile of HIV 
Pr55Gag resembles trimeric size of Pr55Gag complex, detail experimental validation such as 
analytical ultracentrifugation and multi-angle light scattering are needed to confirm 
whether the full length HIV Pr55Gag exists as a stable trimer in solution. 
Previous works have reported that the oligomerization state of the C-terminus truncated 
Gag (Pr50GagΔp6) changes upon variation of salt and nucleic acid concentrations, it will be 
important to define the properties of the Pr55Gag proteins under these experimental 
conditions and contrast them with the property of Pr50GagΔp6. 
The ability to produce full-length recombinant HIV-1 Pr55Gag enables a large number of 
previously difficult biochemical and biophysical experiments to be carried out. It is 
anticipated that these analyses will significant enrich our collective understanding of HIV-1 
particle formation, and to define the mechanism on how HIV-1 utilize ESCRT proteins to 
facilitate the viral assembly and release process. 
2.7. Conclusion 
We have successfully over-expressed and purified recombinant Pr55Gag using a heterologous 
bacterial expression system, and without the need of a solubility tag. The resultant 
recombinant protein is immuno-reactive by Western blotting using a specific anti-HIV capsid 
monoclonal antibody, and forms virus-like particles. The ability to generate large quantities 
of recombinant Pr55Gag will facilitate structural and functional studies of HIV Gag and allow 
us insights into the proteolytic processing, conformational and oligomerization changes that 
occurs during viral maturation. 
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Chapter 3: The thermodynamics of Gag-RNA interaction regulate 
the assembly of HIV 
In vitro analysis of recombinant Gag lacking p6 domain has helped us understand key stages 
of the HIV assembly process. Availability of recombinant full length Gag now gives the 
necessary tool to utilize different in vitro techniques and decipher the complete picture of 
various HIV-1 Gag interactions. The Gag-RNA complex is one of the major interaction that 
can now be better understood using the Pr55Gag. In particular the thermodynamics of the 
Gag-RNA as well as Gag-Gag assembly process, which have been suggested to be energy 
dependent in previous studies 143. Moreover, Gag undergoes a conformational change from 
a folded state in the cytoplasm where the MA and CA of one Gag molecule are in close 
proximity to an extended state in higher order oligomeric form on the plasma membrane. 
Does the interaction with RNA vary as Gag changes its conformation in solution? The 
changes in energy requirements going from a lower oligomeric form in the cytoplasm to a 
higher order oligomeric form on the plasma membrane, can be studied using techniques 
such as isothermal titration calorimetry (ITC). We have tried to answer a few of these 
question in our next study. Availability of recombinant Pr55 Gag helped us to directly 
compare assembly patterns of both Pr55Gag and the previously studied Pr50 Gag ∆p6. Such 
comparisons can help us to determine if the p6 domain has a bigger role in the viral life 
cycle, or is its requirement just limited in the budding of the virus.  
3.1.  Publications relating to this chapter 
Hanumant S. Tanwar, Keith K. Khoo, Megan Garvey, Lynne Waddington, Andrew Leis, 
Marcel Hijnen, Tony Velkov, Geoff J. Dumsday, William J. McKinstry and Johnson Mak 
(2016). Under Review Nucleic Acids Res. 
3.2.  Abstract  
The details of HIV assembly are not well defined due to the scarcity of full-length 
recombinant Pr55Gag. We have solved this problem and applied in vitro systems to dissect 
the early steps of HIV assembly. Here we show pre-loading of Gag with nucleic acids better 
supports virus formation over nucleic acid-free Gag, indicating Gag with pre-bound RNA is 
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the nucleation point for assembly. Thermodynamic analysis showed that the binding 
between RNA and HIV Pr55Gag is an energetically favourable reaction (∆G<0) that is further 
enhanced by the oligomerization of Gag. Gag molecules that are able to form higher-order 
oligomers have binding preference toward immature virus designated A-rich RNA motifs 
over cytoplasmic designated GU-rich RNA motifs. Our data provided direct evidence on how 
nucleic acid sequences and the oligomeric state of Pr55Gag regulate HIV assembly. 
Importantly, this work provides a platform to determine the biophysical properties that 
regulate HIV assembly in general.  
3.3. Introduction 
The HIV-1 Gag precursor protein (Pr55Gag), is the major structural protein that orchestrates 
HIV assembly. The major domains in Pr55Gag include matrix, capsid, nucleocapsid and p6Late. 
The nucleocapsid (NC) domain is responsible for genomic RNA packaging; the capsid (CA) 
domain mediates the key interactions to promote Gag-Gag oligomerization; the matrix (MA) 
domain targets the protein to assembly sites at the plasma membrane; while the p6 domain 
facilitates the egress of virus particles (for review see 1,31,144).  C-terminus truncated 
recombinant Pr50GagΔp6, upon the addition of nucleic acid, has previously been shown to 
assemble in vitro, forming virus-like particles (VLPs) in the absence of other viral proteins 
82,145. 
It is generally accepted that nucleic acid binds to Gag and acts as a scaffold for Gag 
oligomerization 78,145,146, although 10 mer or less oligonucleotides are not sufficient to 
bridge 2 Gag molecules to support assembly 82,147. Cellular imaging and 
immunoprecipitation studies have suggested that nucleic acid initially binds to cytosolic Gag, 
therefore promoting the formation of low order oligomers of Gag in the cytosol; higher 
order Gag oligomers only occur upon Gag binding to the plasma membrane 62,75,120,148. 
However, cytoplasmic HIV-1 RNA has also been shown to traffic to the membrane by passive 
diffusion independently of Gag, suggesting RNA could bind to Gag molecules on the plasma 
membrane to initiate assembly 149. Clearly, the sequence of events between nucleic acid 
binding and Gag oligomerization that lead to virus assembly are still unclear.  
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Following trafficking of Gag to the plasma membrane, high order oligomerization of Gag 
assembly occurs, with NC-nucleic acid binding, Gag CA-CA interaction and plasma 
membrane targeting being three major contributors to the assembly process 150. Many 
studies have proposed the mechanisms of how Gag is specifically targeted via the matrix 
domain to the plasma membrane 77,151,152. However, the mechanisms of how high order 
oligomerization proceed thereafter remains unclear. Moreover, it is also not known what 
thermodynamic properties drive the virus assembly process.     
Apart from the packaging signal (Psi) of the genomic RNA that is involved in the 
encapsidation of viral genome, the contributions from the rest of the viral RNA sequence to 
the assembly process is not well defined. Early studies have indicated that the mature 
nucleocapsid domain on its own displays preferential binding to selected nucleic acid 
sequence motifs in addition to the Psi packaging sequences 147,153,154. Studies comparing Psi 
and non-Psi RNA binding to C-terminal truncated Gag protein suggested differences in 
electrostatic properties of RNA sequences were also important for facilitating binding 
between Gag and viral RNA sequences 67. Recent cross-linking immunoprecipitation 
experiments have shown that different RNA motifs interact with Gag at different stages of 
virus biogenesis, implying a specific relationship between the oligomeric state of Gag and 
the type of RNA sequence that Gag binds to during assembly 79. However, direct evidence of 
this relationship has yet to be shown.   
A key bottleneck in acquiring fundamental information about the mechanistic details of 
Gag assembly has been the limited availability of full-length recombinant Gag protein, as 
large quantities of full-length recombinant Gag are difficult to produce 82,113. Here, we have 
produced large quantities of recombinant Pr55Gag and used in vitro systems to study the 
early steps of HIV assembly. We directly demonstrate more efficient virus-like particle 
formation when nucleic acid binds to authentic full-length Gag prior to high order Gag 
oligomerization. Additionally, using isothermal titration calorimetry (ITC), we show that both 
the oligomerization of Gag and Gag binding with RNA sequences are thermodynamically 




3.4. Material and methods 
3.4.1. Production and purification 
3.4.1.1. Media 
Defined medium (DM1) used for seed cultures contained per litre: KH2PO4, 13.3 g; 
(NH4)2HPO4, 4.0 g; citric acid, 1.7 g; glucose, 10 g; MgSO4.7H2O, 0.62 g; kanamycin, 50 mg; 
thiamine hydrochloride, 4.4 mg; and trace salts solution, 5 mL. Defined medium (DM2) used 
in the bioreactors contained per litre: KH2PO4, 10.6 g; (NH4)2HPO4, 4.0 g; citric acid, 1.7 g; 
glucose, 25 g; MgSO4.7H2O, 1.23 g; kanamycin, 50 mg; thiamine hydrochloride, 4.4 mg; and 
trace salts solution, 5 mL. The trace salts solution contained per litre: CuSO4.5H2O, 2.0 g; 
NaCI, 0.08 g; MnSO4.H2O, 3.0 g; Na2MoO4.2H2O, 0.2 g; boric acid, 0.02 g; CoCl2.6H2O, 0.5 g; 
ZnCl2, 7.0 g; FeSO4.7H2O, 22.0 g; CaSO4.2H2O, 0.5 g and H2SO4, 1 mL. As required, glucose, 
magnesium, trace salts, thiamine and kanamycin were aseptically added as concentrated 
stock solutions to media after sterilisation. 
3.4.1.2. Seed cultures 
Primary seed cultures of pET28a vector containing the Gag expressing gene (described in 
chapter 2) were prepared from single colonies taken from a fresh transformation plate, and 
grown in 10 mL of DM1 (in a 30 mL bottle). The cultures were incubated at 37 ºC shaking at 
200 rpm for 23 h. A volume (0.5 mL) of the primary seed culture was used to inoculate 
500mL of DM1 (in a 2 L Erlenmeyer flask). These secondary seed cultures were incubated at 
37 °C shaking at 200 rpm for 16 h. 
3.4.1.3. Protein expression in 2L stirred-tank bioreactors 
Recombinant HIV Gag proteins were produced in 2 L stirred tank bioreactors connected to a 
Biostat B (Sartorius Stedim, Germany) control system. The initial volume of medium in the 
bioreactor was 1.6 L and glucose was used as the carbon source. A volume of the secondary 
seed culture was added to the bioreactor to attain an initial optical density (measured at 
600 nm) of 0.25. Foaming was controlled via the automatic addition of 10% (v/v) 
polypropylene glycol 2025; 3 mL of the antifoam solution (Sigma, Antifoam 204) was added 
41 
 
prior to inoculation.  The pH set-point was 7.0 and controlled by automatic addition of 
either 10% (v/v) H3PO4 or 10% (v/v) NH3 solution. The dissolved oxygen set-point was 30% of 
saturation and a two-step cascade control was used maintain the dissolved oxygen above 
the specified set-point. The agitator speed ranged from 500 rpm to 1200 rpm and airflow 
(supplemented with 5 % pure O2) ranged from 0.3 L min-1 to 1.5 L min-1. The ratio of air to 
oxygen was manually changed as required. To assist with correct folding of the Gag proteins, 
the medium was supplemented with 50 μM ZnSO4 added 1.8 h after inoculation. A high cell 
density fed-batch process was used, with the feed solution comprised of 400 mL of 660 g L-1 
glucose solution to which 40 mL of 1 M MgSO47H2O was added. The feed flow rate was 21 
mL hr-1 and commenced once the initial glucose supply was exhausted (typically 8 to 9 hr 
after inoculation). Two hours after the fed-batch process was initiated the bioreactor 
temperature set-point was reduced to 18°C, with culture temperature dropping to 19 °C 
within 30 min. After cooling, protein expression was induced via the addition of 1 mM IPTG 
and 0.02 % (w/v) arabinose and the feed flow rate reduced to 4 mL hr-1. Cells were 
harvested by centrifugation (12000 g, 4 °C, 10 min) 22 to 23 h after inoculation and cell 
pellets stored at -80 ⁰C.  
3.4.1.4. Protein purification 
Cell pellets (~200 g) were thawed and resuspended in 1.0 L of ice cold lysis buffer (1 M NaCl, 
50 mM TRIS-HCl pH 8.0, 5 mM MgCl2, 10 mM imidazole, 1 (v/v)% Tween-20, 10% (v/v) 
glycerol, 5 mM DTT) containing 50,000 units of DNase I, 5 mM benzamidine-HCl and 1 mM 
PMSF. The cell suspension was homogenized (EmulsiFlex-C5 homogenizer, Avestin®) pre-
chilled to 4 oC, three times at 700 bar pressure. The lysate was clarified by centrifugation 
12,000 g, 4°C, 30 min), and the supernatant filtered using a 0.45 μm Stericup® filter 
(Millipore). 
3.4.1.5. IMAC (Immobilized Metal Affinity Chromatography) 
The supernatant was loaded at 5 mL min-1 onto a 30 mL HisTRAP fast flow IMAC column 
(consisting of 6 x 5 mL cartridges connected in series; GE Healthcare) using a MINIPULS® 
peristaltic pump (Gilson®).  The column had previously been equilibrated with 5 column 
volumes (CV) binding buffer (1.0 M NaCl, 50 mM TRIS-HCl pH 8.0, 5 mM MgCl2, 10 mM 
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imidazole, 1 % (v/v) Tween-20, 10 % (v/v) glycerol, 5 mM DTT). The column was washed 
with 10 CV wash buffer (1.0 M NaCl, 50 mM TRIS-HCl pH 8.0, 5 mM MgCl2, 25 mM imidazole, 
1 % (v/v) Tween-20, 10 % (v/v) glycerol, 5 mM DTT) and bound proteins eluted with 5 CV 
elution buffer (1.0 M NaCl, 50 mM TRIS-HCl pH 8.0, 5 mM MgCl2, 250 mM imidazole, 1 % 
(v/v) Tween-20, 10 % (v/v) glycerol, 5mM DTT). Pr55Gag eluting from the IMAC column was 
concentrated to ~ 3.0 mg mL-1 using a centrifugal concentrator (Amicon Ultra-15, 10,000 
molecular weight cut-off membrane; Millipore).  
3.4.1.6. Size exclusion chromatography  
The concentrated protein (5x 10 mL) was then fractionated by size exclusion 
chromatography (SEC) using a Superdex 200 26/60 column (GE Healthcare) previously 
equilibrated in SEC buffer (50 mM TRIS-HCl, 1.0 M NaCl, 5 mM DTT, pH 8.0) using a  
ÄKTApurifier chromatography workstation (GE Healthcare). Peak fractions (UV 280nm) 
containing Pr55Gag were collected, pooled and concentrated to 1 - 2 mg mL-1 as described 
above, and snap frozen in liquid nitrogen before storage at -80 ⁰C. 
3.4.2. Crosslinking assay 
Protein was buffer exchanged into 1x Na/K 10mM phosphate buffer containing 136mM Cl 
(pH 7.4) with different NaCl concentrations and concentrated to 1 mg mL-1. Yeast tRNA (10 
% (w/w) ratio of nucleic acid to protein) was added to the protein solution and incubated for 
30 min at room temperature, followed by addition of paraformaldehyde (PFA) (final 
concentration of 0.2% w/v). After incubating the solution for further 30 min at room 
temperature, the crosslinking was stopped by addition of 50 μL of 3M TRIS-HCL pH 8.0. 
Samples were centrifuged 10 min at 10,000 g and supernatants were analyzed by size 
exclusion chromatography using a Superdex 200 10/30 column (GE Healthcare), previously 
equilibrated in PBS with respective NaCl concentrations. Peak fractions were concentrated 
to 2 mg mL-1 as previously described. Fractions were electrophoresed on a NuPAGE® Novex® 
3-8% TRIS-Acetate protein gel under denaturing conditions before being transferred onto 
nitrocellulose membranes for Western analysis. 
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3.4.3. Electron Microscopy 
Pr55Gag and Pr55GagΔp6 were concentrated to 2.0 mg mL-1 in 50 mM TRIS-HCL pH 8.0 
containing 1.0 M NaCl and 10 mM dithiothreitol and mixed with TG30 at a nucleic acid to 
protein ratio of 4% (w/w) prior to dialysis against 50 mM TRIS pH 8.0 containing 150 mM 
NaCl and 10 mM dithiothreitol overnight at 4°C. Particles were imaged using both negative 
stain transmission electron microscopy and cryo-electron microscopy.  
For negative stain imaging, the stock solution was diluted 100-fold to give a single layer of 
well-separated particles in most fields of view. Carbon-coated grids were glow discharged in 
nitrogen prior to use to facilitate sample spreading. Aliquots of approximately 4 μL were 
pipetted onto each grid and allowed to settle for 30 s. Excess sample was drawn off with 
filter paper, and the remaining sample stained with a drop of 2 % aqueous phosphotungstic 
acid. Again, excess liquid was drawn off with filter paper. Grids were air dried until required.  
Samples were examined using a Tecnai 12 Transmission Electron Microscope (FEI, 
Eindhoven) at an operating voltage of 120KV.  Images were recorded using a Megaview III 
CCD camera and AnalySIS camera control software (Olympus.) 
For cryo-electron microscopy, virus particles were prepared, processed and imaged as 
previously described 155. 
3.4.4. Sucrose gradient 
For the nucleic acid pre-loading method of in vitro assembly, protein (2.5 mg mL-1) and yeast 
tRNA (Sigma-Aldrich) or a DNA 30-mer oligonucleotide with alternating TG motifs (TG30; 
Macrogen) at a 10 % (w/w) ratio of nucleic acid to protein were mixed in 50 mM TRIS, 0.5 M 
NaCl, pH8.0 and slowly diluted 5-fold with 50 mM TRIS, pH 8.0. Reaction mixtures were 
incubated at room temperature for 2 h. In the nucleic acid post-loading method of 
assembly, yeast tRNA or oligonucleotide was added to Gag protein (0.5 mg mL-1) in TRIS-
Buffered Saline (TBS) [50 mM TRIS, 150 mM NaCl, pH 7.5] and incubated at room 
temperature for 2 h. The buoyant density of the particles produced and their in vitro 
assembly efficiency was assessed by layering the assembly reaction mixture onto a 32.5 to 
55 % (w/w) linear sucrose gradient in TBS. Assembled HIV-1 Gag samples were layered onto 
the gradient and centrifuged for 16 h at 110,000  g (SW41 rotor: Optima L-90k 
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ultracentrifuge; Beckman). 750 μL fractions were collected from the top in separate 1.5 mL 
tubes after completion of the run and prepared for trichloroacetic acid (TCA) precipitation.  
3.4.5. TCA Precipitation 
350 μL of 50% (w/v) TCA was added to each fraction and incubated at 4°C for 30 min. Tubes 
were centrifuged at 14,000 g for 10 min at 4 °C and the pellet was resuspended in 200 μL of 
pre-chilled acetone and incubated for 5 min at 4 °C. The centrifugation step was repeated 
and excess supernatant aspirated and tubes air dried. The dried pellet was resuspended in 
20 μL of 4x NuPAGE® reduced LDS Sample Buffer (Life Technologies) and heated for 5 min at 
95 °C. Samples were briefly centrifuged and 10 μL of each sample was loaded onto a 
NuPAGE™ 4-12% Bis-TRIS Midi gel and electrophoresed using NuPAGE® MES SDS running 
buffer (Life Technologies) at 150 volts. 
3.4.6. Western blot 
PAGE gels were transferred to a Nitrocellulose membrane (PerkinElmer) using XCell II™ Blot 
Module (30 volts for 60 mins), and the membrane blocked overnight in blotto (5 % (w/v) 
skim milk powder in TBS + 0.05 % (v/v) Tween-20) at 4 ⁰C. Membrane was washed 3x with 
wash buffer (TBS + 0.05% (v/v) Tween-20) for 5 min each and probed with a mouse anti-CA 
monoclonal antibody (Hybridoma Clone 183-H12-5C; NIH AIDS Reagent program) for 1 h at 
room temperature. Membrane was washed 3x with wash buffer, incubated with a 
secondary goat anti-mouse IRDye® 800CW conjugate (LI-COR; diluted1:30,000 in blotto) for 
1 hr at room temperature. Membrane was washed again 3x and analysed using an 
ODYSSEY® CLx system (LI-COR). 
3.4.7. Isothermal Titration Calorimetry  
Isothermal titration calorimetry (ITC) experiments were performed at 30 °C using a Microcal 
Auto-ITC200 MicroCalorimeter (Malvern). For each ITC experiment, the cell contained soluble 
Gag protein (6 – 10 μM) in TBS with 1mM TCEP and the syringe contained 15 – 50 μM of the 
DNA 30-mer oligonucleotide with alternating TG motifs (TG30) or RNA 20-mer 
oligonucleotides with 4 repeating GU-rich (5’GAUGG3’; 5’UGUGG3’) or A-rich (5’GAGAA3’; 
5’AAGGA3’) sequence motifs. The SL3 sequence is based on NL4.3 HIV proviral DNA, and the 
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20mer SL3 RNA sequence is 5’GGACUAGCGGAGGCUAGUCC3’. DNA and RNA 
oligonucleotides were purchased from Macrogen and Integrated DNA Technologies, 
respectively, and dissolved in TBS with 1mM TCEP. The volume of the first injection for each 
ITC run was set to 0.4 μL over 0.8 s to minimize the experimental impact caused by dilution 
effects at the injection syringe tip; this initial injection was excluded from data analysis. The 
first injection was followed by 25 injections of 1.5 μL over 3 s or 38 injections of 1 μL over 2 s 
each with the interval between each injection set to 300 s. The reference power was set to 5 
μcals-1. The syringe stirring speed was set to 750 rpm.  
A baseline was drawn by linear extrapolation using the data points collected from control 
experiments and subtracted from the whole data set to correct for the heat of dilution. The 
total heat signal from each injection was determined as the area under the individual peaks 
and plotted against the [nucleic acid]/[Gag] molar ratio. The corrected data were analyzed 
to determine number of binding sites (n), and molar change in enthalpy of binding (ΔH) in 
terms of a single site model derived as follows: 
The quantity r is defined as the moles of nucleic acid [D] bound per mole of protein [P] 
with an association constant (Ka): 
ݎ ൌ ௄ೌሾ஽ሿଵା௄ೌሾ஽ሿ                                        (Eq 1) 
Solving Eq 1 for Ka leads to: 
ܭ௔ ൌ ௥ሺଵା௥ሻሾ஽ሿ                         (Eq 2)                     
Since the total concentration of nucleic acid [D]T in the cell is known, it can be represented 
by Eq 3 wherein [P]T equals the total protein concentration in the cell and n the number of 
binding sites: 
 ሾܦሿ் ൌ ሾܦሿ ൅ ݊ݎሾܲሿ்                                                (Eq 
3) 
Since Eq 3 shows nr[P]T=[PD], the fraction of sites occupied by the nucleic acid, combining 
Eqs 2 and 3 leads to: 
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ݎଶ െ ݎ ቂ ሾ஽ሿ೅௡ሾ௉ሿ೅ ൅
ଵ
௡௄ೌሾ௉ሿ೅ ൅ ͳቃ ൅
ሾ஽ሿ೅
௡ሾ௉ሿ೅ ൌ Ͳ                                 (Eq 4) 
Solving the quadratic for the fractional occupancy (r) gives: 









ଶ െ ସሾ஽ሿ೅௡ሾ௉ሿ೅቉                             (Eq 5) 
The total heat content (Q) of the solution in the volume of the sample cell (Vo; determined 
relative to zero for the apo-species) at fractional saturation r is given by Eq 6, where ΔH 
represents the molar heat of nucleic acid binding: 
ܳ ൌ ݊ݎሾܲሿ்ȟ ௢ܸ                                                                                    (Eq 6) 
Substituting Eq 5 into Eq 6 gives: 









ଶ െ ସሾ஽ሿ೅௡ሾ௉ሿ೅቉                          (Eq 
7) 
The total heat content, Q can be calculated as function of n, Ka, 'H because [P]T, [D]T and Vo 
are known experimental parameters. The parameter Q defined in Eq 7 only applies to the 
known starting volume of protein solution in the sample cell (Vo). In order to correct for the 
displaced volume (Vi), the change in heat content Q(i) at the end of the ith injection is 
defined by Eq 8 to obtain the best fit for n, Ka, and 'H by standard Marquardt methods until 
no further significant improvement in fit occurs with continued iteration.   
'ܳሺ݅ሻ ൌ ܳሺ݅ሻ ൅ ௗ௏௜௏௢ ቂ
ொሺ௜ሻାொሺ௜ିଵሻ
ଶ ቃ െ ܳሺ݅ െ ͳሻ               (Eq 8) 
All data fitting operations were performed with Origin V7.0 software (OriginLab, 
Northampton, MA). 
The Gibbs free energy ('G0) was calculated from the fundamental equation of 
thermodynamics Eq 9: 





3.5.1. Pr55Gag has a similar in vitro oligomerization profile to Pr50Gag∆p6  
Much of our knowledge about the biochemical and biophysical details of HIV Gag assembly 
is derived from the truncated Pr50GagΔp6 53,82,84,156,157, due to its more stable property after 
production. We have now produced full-length C-terminal His-tagged Pr55Gag and utilized 
this to evaluate HIV assembly in vitro. Cryo Electron Microscopy (EM) analysis of mammalian 
cell derived Gag-only VLPs showed the His-tag modification did not affect VLP formation 





Figure 3.1:  
Pr55Gag and Pr50Gag∆p6 follow similar oligomerization and assembly pattern. In vitro 
assembled particles from recombinant (A) Pr55Gag and (B) Pr50Gag∆p6 were negatively stained 
and analysed using Transmission Electron Microscopy (TEM). See also Figure S2. Size 
exclusion chromatography (SEC) of (C) Pr55Gag and (D) Pr50Gag∆p6 assembled in the presence 
of nucleic acid and crosslinked. Blue trace represents gel filtration profile in the absence of 
nucleic acid. Fractions following SEC were analysed by Western blotting using anti-CA for 
both (E) Pr55Gag and (F) Pr50Gag∆p6. Sucrose gradient analysis of mammalian cell derived VLPs 
from cells transfected with (G) wild type Gag and C-Terminus His Tagged Gag. Analysis 
indicates VLPs derived from mammalian cells are mostly observed in fractions 6-10 (boxed). 
Sucrose gradients showed that adding IP6 to the assembly of recombinant (H) Pr55Gag and (I) 
Pr50Gag∆p6 promoted formation of higher order complexes, which exhibited similar 
fractionation positions as with mammalian cell derived Gag VLP. 
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Oligomerization and consequently in vitro assembly of Pr55Gag or Pr50GagΔp6 particles was 
induced through the addition of either a 30-mer DNA oligonucleotide with repeated TG 
motifs (TG30) or yeast tRNA as in previous studies 82. Transmission Electron Microscope 
(TEM) imaging of the in vitro assembly reaction revealed formation of similar sized spherical 
particles for both Pr55Gag (Figure 3.1A, Supplementary Figure S2) and Pr50GagΔp6 (Figure 3.1B, 
Supplementary Figure S2), confirming the functionality of our recombinant Pr55Gag protein. 
Elution profiles for the assembled complexes of both Pr55Gag and Pr50GagΔp6 migrated 
similarly on a size exclusion column (Figure 3.1C, D), and Western blot of peak elution 
fractions (Figure 3.1E,F) showed these two recombinant proteins share many similar 
biophysical properties and oligomerization capacity.  
Assembled Gag complexes were centrifuged through a sucrose gradient, and the proportion 
of assembled Pr55Gag and Pr50GagΔp6 complexes which feature a similar sucrose gradient 
fractionation profile to mammalian cell derived HIV-1 Gag VLPs (fractions 6-10 as boxed in 
Figure 3.1G) were estimated. Sucrose gradient analyses of in vitro assembled products are in 
agreement with previous work that the addition of IP6 promoted the formation of higher 
order complexes 53 (Figure 3.1H,I). A large portion of recombinant proteins migrated at 
similar fractions to soluble proteins, implying that in vitro induced VLPs are more fragile 
than mammalian cell derived VLPs and are more prone to fall apart during sucrose gradient 
ultracentrifugation (Figure 3.1H,I). Overall, our results demonstrate that the recombinant 
full-length Pr55Gag display similar in vitro oligomerization and assembly profile as Pr50GagΔp6, 
validating our recombinant Pr55Gag as a good model for studying HIV assembly. 
3.5.2. Pre-incubation of Pr55Gag with nucleic acid enhances particle assembly  
It is established that high order oligomerization of Gag occurs at the plasma membrane 
during assembly and that nucleic acid binding, Gag oligomerization and plasma membrane 
targeting all contribute to the assembly process 150. However, the exact mechanism and 
sequence of events of nucleic acid binding and subsequent oligomerization leading to 
assembly are poorly defined. Imaging studies have suggested that Gag could bind to nucleic 
acid and form low-order oligomers in the cytosol prior to trafficking to the plasma 
membrane for assembly 75,120 (pre-load assembly pathway). Alternatively, both Gag and RNA 
could traffic separately to the plasma membrane and interact together to initiate assembly 
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(post-load assembly pathway) 149 (Figure 3.2A). We tested the two models of assembly in 
vitro and measured the efficiency of particle formation using sucrose gradient separation as 
above (a schematic representation of the migration of assembled Gag complexes following 
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centrifugation in a typical sucrose gradient run is depicted in Figure 3.2B).  
Comparing the pre- and post-nucleic acid loading methods of in vitro assembly in the 
presence of TG30 and IP6, our results demonstrated that pre-loading of Gag with nucleic 
Figure 3.2: 
 Pre-incubation of Pr55Gag with nucleic acid and IP6 enhances particle assembly. (A) Schematic of 
possible Gag assembly pathways. (B) Schematic representation of a sucrose gradient tube following 
centrifugation with assembled VLPs migrating down the gradient but soluble protein remaining on top.
(C) Sucrose gradient analysis indicating limited VLP formation in Pr55Gag WM (a variant that does not 
readily form VLPs) with TG30 and Pr55Gag with TG4 (a short oligomer that is not long enough to 
support VLP formation).  (D) Increase in VLP formation occurred when Pr55Gag and Pr50Gag∆p6 were pre-
incubated with nucleic acid and IP6. 
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acids in vitro has a greater efficiency to support virus particle formation (Figure 3.2D). The 
negative controls for our assay, employing Pr55GagW316A,M317A 83 or with a shorter 4-mer 
oligonucleotide (TG4), displayed decreased ability for the formation of VLPs (Figure 3.2C). 
Our results suggest that binding of nucleic acids to Gag prior to high order Gag 
oligomerization improves the efficiency of particle assembly.  
3.5.3. Oligomerization during HIV Pr55Gag assembly is an energetically favourable process 
 
Figure 3.3:  
Binding between Psi SL3 RNA and Gag is an energetically favourable reaction enhanced by 
the oligomerization capacity of Gag. The top panels show the differential heat released 
following baseline subtraction and the bottom panel shows ITC binding curve indicating heat 
released per mole of oligonucleotide titrated when (A) Psi SL3 RNA (40 μM) and (B) Psi SL3 
DNA (40 μM) were injected in 1.5 μL aliquots into 8 μM of Pr55Gag, Pr50GagΔp6, Pr55Gag WM, 
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p15NC-SP2-p6 and p7NC. (C) TG30 DNA (15 μM) was injected in 1 μl aliquots into 8 μM of 
Pr55Gag, Pr50GagΔp6, Pr55GagWM, p15NC-SP2-p6 and p7NC. See also Figure S3. 
The binding of RNA to Gag and the oligomerization of Gag molecules are two of the basic 
components of viral assembly. However, it is currently not known what is the driving force 
or the source of energy for this assembly process. We first used ITC to characterize the 
binding between Gag protein and the packaging signal stem loop 3 RNA (Psi SL3 RNA), a 
region of the viral RNA involved in genomic packaging and known to bind to NC with high 
affinity 135,154. Interaction of Psi SL3 RNA with the mature nucleocapsid domain (p7NC) and 
the processed Gag intermediate p15NC-SP2-p6 produced a favourable energy release of ~5-6 
kcal mol-1 as measured by the maximum heat energy release or the binding enthalpy (∆H) 
during ITC titrations of Psi SL3 RNA into the NC protein (Figure 3.3A and Supplementary 
Figure S3). In contrast, more heat energy was released in the interaction of Psi SL3 RNA with 
full length Pr55Gag [~17 kcal mol-1] and Pr50GagΔp6 [~17.5 kcal mol-1] compared to that with 
p7NC. Notably, interaction of Psi SL3 RNA with the oligomeirzation-impaired full-length 
mutant, Pr55GagW316A,M317A, released about 40% less energy [~10 kcal mol-1] compared to 
wild type Pr55Gag, suggesting that Gag-Gag interactions increased its favourable binding 
enthalpy with Psi SL3 RNA. In contrast to the oligomerization impaired Gag mutant 
(Pr55GagW316A, M317A) and processed NC proteins (p15NC-SP2-p6 and p7NC), wild type Pr55Gag had 
a large gain of detectable entropy during ITC reaction when Psi SL3 RNA was used 
(Supplementary Figure S3A). As entropy is driven largely by water displacement upon 
hydrophobic interaction (such as Gag-Gag oligomerization) 158, these data support the 
contributions of Gag oligomerization in this process.  The binding affinities for Pr55Gag [Kd = 
0.081 ± 0.025 μM] and Pr55GagW316A, M317A [Kd = 0.088 ± 0.035 μM] with SL3 RNA did not 
differ significantly, although slightly smaller Kd were measured for p15NC-SP2-p6 [Kd = 0.057 ± 
0.011 μM] and p7NC [Kd = 0.048 ± 0.023μM] (Supplementary Figure S3C). Our ITC results 
demonstrate that the binding of Psi SL3 RNA to Gag is energetically favourable (∆G<0), with 
an increased capacity of Gag to oligomerize further enhance the favourable release of 
energy (Supplementary Figure 3.3A).    
As several studies on Gag-nucleic acid binding have utilized DNA sequences as a 
comparatively more stable alternative to RNA, we next investigated if the ITC binding profile 
would change if the type of nucleic acid backbone were switched from RNA to DNA. 
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Qualitatively, the binding curves were less sigmoidal in shape indicating that DNA Psi SL3 
binds to Gag with a lower binding affinity compared to RNA Psi SL3. However, similar to Psi 
SL3 RNA, the interaction of Psi SL3 DNA with oligomeric Gag also released more energy as 
well as had a higher entropy gain when compared to oligomeric-deficient forms of Gag 
(Figure 3.3B and Supplementary Figure S3B). A similar relationship was seen when TG30 
DNA was used as the nucleic acids substrate (Figure 3.3C), although the hyperbolic binding 
curves observed with TG30 binding to Pr55Gag and Pr50GagΔp6 indicate a lower binding affinity 
compared to the more sigmoidal curves observed with the Psi SL3 binding interaction. The 
hyperbolic nature of the binding curves obtained with TG30 DNA precluded a quantitative 
thermodynamic analysis. Nonetheless, our data suggests that different nucleic acid 
sequence might bind to Gag with different mechanisms, with oligomerization influencing 
the binding profile.   
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3.5.4. Gag that has greater capacity to oligomerize displays more energetically favourable 
binding to the identified Gag-interacting RNA sequence motifs present in the  
immature virion over those in cytosolic sequences  
 
Figure 3.4: 
 ITC analysis of Gag-RNA binding show more energetically favourable binding of Gag to A-
rich over GU-rich RNA. (A) Schematic of Gag-RNA binding specificity during viral assembly. 
ITC binding curves indicating heat released per mole of oligonucleotide titrated when 40 μM 
of (B) GAUGG4 (GU-rich) and GAGAA4 (A-rich) RNA and (C) UGUGG4 (GU-rich) and AAGGA4 
(A-rich) RNA were injected in 1.5 ul aliquots into 8 μM of Pr55Gag, Pr50GagΔp6, Pr55Gag WM, 
p15NC-SP2-p6 and p7NC. See also Figure S4. 
During the assembly of HIV, there are only 2 sets of SL3 sequences in the packaged HIV 
dimeric RNA genome. As a result, most of the 1500- 5000 Gag molecules in the assembled 
virion must bind to other segments of the RNA genome. However, the role these non- 
packaging segments of the RNA genome play in viral assembly still remains unanswered. HIV 
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Gag was previously reported to transiently interact with different RNA sequence motifs 
during the viral assembly process 79, and it was suggested that cytosolic Gag consisting of 
low-order Gag oligomers would interact with GU-rich RNA sequence motifs but high-order 
Gag oligomers in the immature virion were more likely to associate with A-rich RNA 
sequence motifs (schematized in Figure 3.4A). Hence, the oligomerization state of Gag could 
be a means for enhancing Gag interaction with the A-rich viral RNA during assembly. 
However, direct evidence has yet to be presented.  
To test this hypothesis, we conducted ITC analyses of Gag interaction with the top 2 RNA 
sequence motifs that were previously identified to interact with HIV Gag either in the 
cytosol (GU-rich motifs: 5’GAUGG3’ and 5’UGUGG3’) or within the immature virion (A-rich 
motifs: 5’GAGAA3’ and 5’AAGGA3’) 79.  Binding of the GU-rich 5’(GAUGG)43’ RNA to 
oligomeric forms of Gag (Pr55Gag and Pr50GagΔp6) resulted in an energy release of about 30 
kcal mol-1, which was ~33% more energy released compared to oligomeric-deficient variants 
of Gag (Pr55GagW316A, M317A, p15NC-SP2-p6 and p7NC) [~20 kcal mol-1 energy release] (Figure 
3.4B), suggesting that oligomerization contributes at least in part to the favourable enthalpy 
release. In support of this, ~33% more energy release was also observed in the interaction 
of the A-rich 5’(GAGAA)43’ RNA with oligomeric [~60 kcal mol-1 energy release] compared to 
oligomeric-deficient forms of Gag [~40 kcal mol-1 energy release] (Figure 3.4B). Agreeably, 
ITC analyses repeated with the second set of GU-rich and A-rich RNA sequence motifs 
(5’UGUGG43’ and 5’AAGGA43’, respectively) produced a similar trend in binding enthalpies 
measured across the Gag constructs (Figure 3.4C). Importantly, across the Gag constructs 
tested, the interaction of the A-rich RNA motifs with Gag consistently released ~2-fold more 
energy compared to that of the GU-rich RNA motifs, suggesting that Gag displays a more 
energetically favourable (∆H) binding to identified Gag-interacting RNA sequence motifs in 
immature virion over those in the cytosol. Furthermore, a higher level of entropy was also 
detected when A-rich RNA motifs were used in ITC experiments (Supplementary Figure S4), 
implying these designated A-rich motifs might better support tight packing of Gag-RNA 
and/or Gag-Gag interaction to induce additional water displacement during the biological 
process. Thus, the additional energy release could in part drive the switch of RNA-binding 
preference of Gag from the cytosolic GU to immature virus A-rich motifs. In addition to the 
more favourable binding enthalpy of A-rich RNA to Gag, calculated binding affinities (kd) 
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from 4 separate sets of ITC A-rich and GU-rich RNA binding curves revealed that oligomeric 
capable Pr55Gag displayed a 4-fold or stronger binding affinity for the immature virus A-rich 
RNA motif over the cytosolic GU-rich RNA motif. This occurrence was not observed when 
oligomeric-deficient forms of Gag (Pr55GagW316A, M317A) were used in parallel experiments 
(Figure 3.5 A, B), consistent with the proposed model that oligomeric Pr55Gag interacts 
preferentially with A-rich RNA 79. Overall, our ITC analyses provide direct evidence on how a 
more favourable binding enthalpy and an increased binding affinity of oligomeric Pr55Gag for 








 Oligomeric Gag has increased binding preference toward A-rich over GU-rich RNA 
sequences. (A) Calculated binding affinities (Kd) from ITC binding curves fitted to a one-site 
interaction model are plotted for Pr55Gag, Pr55GagWM, p15NC-SP2-p6 and p7NC. Sets 1 and 2 
represent Kd values obtained from replicate Gag interactions with GUAGG4 (GU-rich RNA) 
and GAGAA4 (A-rich RNA). Sets 3 and 4 represent Kd values obtained from replicate Gag 
interactions with a second set of GU-rich and A-rich RNA (UGUGG4 and AAGGA4, 
respectively). (B) Calculated binding affinities (Kd) for Pr55Gag and Pr55GagWM for each set of 
interactions (as above) were tabulated and the fold difference between GU-rich and A-rich 
RNA binding affinities for each set were calculated. The average fold difference across the 4 
sets is highlighted in bold. (C) Proposed model for Gag trafficking and viral RNA interaction 




The trafficking of Gag and RNA to the plasma membrane of the host cell during assembly 
has been the focus of many studies, but the sequence of events are unclear. An early study 
using fluorescence resonance energy transfer suggests that genome packaging in HIV-1 
starts in the cytoplasm wherein a few Gag molecules interact with RNA 159. It is proposed 
that the Gag-RNA complex is then targeted to the plasma membrane where higher order 
oligomerization occurs 160,161, and several other imaging and immunoprecipitation studies 
concur with this proposed model 62,75,120. However, a recent study carried out using total 
internal reflection fluorescence revealed that RNA could travel to the plasma membrane by 
passive diffusion with or without the presence of Gag 149. Our sucrose gradient analyses 
directly compare these two assembly pathways in vitro, and shows better particle formation 
efficiency occurs when Gag first bind to nucleic acid prior to high order Gag oligomerization. 
It is important to acknowledge that the assembly of HIV in vivo is likely to be much more 
complicated than our reductionist in vitro system, where competing interactions (such as 
protein-protein, protein-nucleic acid and viral-host factors) and local concentrations of viral 
assembly components would have significant impact on the outcome of the viral assembly 
process. Notwithstanding, our data showed that Gag proteins that are pre-mixed with 
nucleic acids are more efficient in supporting higher order Gag oligomerization, suggesting 
that Gag with pre-bound RNA is likely to act as a nucleation point for high order Gag 
assembly in vivo.  
Our thermodynamic analyses showed that Gag-RNA binding was energetically favourable in 
terms of free energy change (∆G<0) and that both Gag-Gag interactions and the type of RNA 
sequence can contribute to the favourable change in enthalpy. Many studies have focused 
on the interaction of nucleic acids with the mature forms of the NC domain to probe the 
chaperone activity 153,162 and nucleic acid binding properties of NC during reverse 
transcription 163,164.  Our ITC studies represent the first thermodynamic characterization of 
the binding interaction between nucleic acids and full length Gag, allowing us to study the 
effects of Gag-Gag interaction and Gag-RNA interaction to energy release. In the context of 
Gag assembly, these ITC analyses reflect the net energy exchange when nucleic acids are 
injected into the Gag-Gag and Gag-RNA complexes. It is important to emphasize that some 
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of the observed energy exchange detected via ITC would be the consequence of Gag-Gag 
oligomerization. Our ITC study with RNA and full length Gag (that is capable to oligomerize) 
suggest that the additional release of energy from Gag-Gag interactions could drive the 
binding of Gag with nucleic acid and the oligomerization of Gag.  
Likewise, our observation that the Gag binding with immature HIV A-rich RNA motifs has a 
greater ∆H than the GU-rich cytosolic Gag-interacting RNA motifs during HIV biogenesis 
suggest the additional energy release could help drive the Gag-complex to interact 
preferentially with A-rich RNA sequences during assembly. Furthermore, our 
thermodynamic analyses indicated that the oligomeric capable Pr55Gag, but not oligomeric-
deficient forms of Gag, have a 4-fold stronger binding affinity for immature virus A-rich RNA 
motifs compared to cytosolic GU-rich RNA sequences. These findings suggest that the 
oligomerization state of Gag could be an additional mechanism for preferential interaction 
of Pr55Gag with A-rich RNA at the late stage of viral assembly. It is known that the HIV-RNA 
genome has a bias towards A-rich codons 165,166. While many of these A-rich sequences 
might be a consequence of G to A hyper mutation from APOBEC3G pressure 167,168, HIV has 
found ways to utilise them to its own gain. Indeed, these A-rich viral sequences are already 
known to be important for RNA trafficking from nucleus to cytoplasm via the RRE-Rev 
relationship 169,170, and also for supporting the synthesis of viral cDNA during reverse 
transcription 171. Now, we have evidence to show that the A-rich codon is important for 
regulating the viral assembly process thermodynamically. Our findings show how the virus 
might derive the energy required to drive the Gag-Gag assembly and the mechanism by 
which HIV-1 assemble. Taken together we propose a model (Figure 3.5C) wherein many Gag 
molecules bind to GU-rich RNA in the cytosol forming low-order oligomers. The Gag-RNA 
complex then traffics to the plasma membrane and acts as a nucleation site for Gag 
assembly; with energy released from Gag-Gag and Gag-RNA interactions to drive higher 
order Gag oligomerization. The high-order Gag complex in turn interacts preferentially with 
A-rich viral RNA sequences with a lower Kd, and the process is further enhanced by the 
additional release of energy by interacting with the A-rich viral RNA sequences to assist in 




3.7. Supplementary Figures 
 
Figure S 1: 
 Increase in production of recombinant His-tagged HIV-1 Pr55Gag Cryo EM analysis of 
mammalian cell derived VLP of (A) Wild type Gag and (B) C-terminus His-tagged Gag. (C) Gel 
filtration profile of the purified recombinant Pr55Gag with the bioreactor protocol, compared 
to the previously published purification method 172. Peak fractions were analysed with (D) 







Figure S2:  
Size distribution analysis of in vitro assembled particles, related to Figure 1. In vitro 
assembled particle size of Pr50Gag ∆p6 (A) and Pr55Gag (B) as analysed by TEM. 
 
 
Figure S3: Binding between Psi SL3 RNA and Gag is an energetically favourable reaction 
enhanced by the oligomerization capacity of Gag, related to Figure 3. Calculated binding 
energies from ITC binding curves fitted to a one-site interaction model plotted for replicate 
Gag protein interactions with Psi SL3 RNA (n=3) (A) and Psi 3 DNA (n=2) (B). Calculated 
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binding affinities are also plotted for replicate Gag protein interactions with Psi SL3 RNA 
(n=3) (C). The mean value is plotted and the error bars represent the s.d.   
Figure S4:  
ITC analysis of Gag-RNA binding show more energetically favourable binding enthalpies of 
Gag to A-rich over GU-rich RNA, related to Figure 4. Calculated binding energies from ITC 
binding curves fitted to a one-site interaction model plotted for replicate Gag protein 
interactions with (A) first set of GU-rich RNA (GAUGG4) and A-rich RNA (GAGAA4) (n=3) and 
(B) second set of GU-rich (UGUGG4) and A-rich RNA (AAGGA4) (n=2). The mean value is 
















Chapter 4: Optimisation of Gag complex assembly conditions for 
structural analyses. 
4.1.  Introduction 
Switching from cytoplasmic RNA interactions to viral A-rich RNA interactions by a 
thermodynamically driven binding, HIV-1 Gag forms higher order oligomers at the plasma 
membrane of the cell. This site on the plasma membrane is also the site for virion release in 
the majority of infected cells 173. One of the mechanism the virus utilizes to stop the 
polymerization of Gag as well as promote the budding of virion, is interaction with the host 
cell ESCRT machinery 174-176. The Gag-ESCRT interaction occurs through the PTAP and YPXL 
(where “X” can vary in sequence and length) motifs on the p6 domain of Gag 115,177. TSG101 
(ESCRT I) mimics binding of an endosomal protein Hrs, which contains a PSAP motif and 
binds to TSG101 for biogenesis of vesicles that bud into multi vesicular bodies (MVB). When 
tested against the PSAP from Hrs under similar conditions TSG101 UEV domain displayed a 
sevenfold weaker binding, than against the PTAP motif of HIV-1 Gag p6 a 53 amino acid 
peptide 39.  
Another ESCRT protein family member that is involved in HIV assembly would be Alix, which 
sits at a juncture between the endosomal-lysosomal trafficking, cell death pathways and 
cytoskeleton 178-180.  These functions of Alix in multiple pathways have to do in part with its 
modular structure which consists of three different domains; Bro I domain, which is known 
to bind to Gag NC domain and plays a role in endosomal membrane targeting181, the V-
domain responsible for YPXL motif binding in Gag although its physiological function is still 
unclear182 and an unstructured C-terminal proline rich domain.  
The budding process of HIV-1 is also accompanied or immediately followed by maturation, 
which is primarily driven by the viral PR cleavage of Gag and Gag-pol precursor. Hence it 
would be interesting to analyse the binding affinity of the full length Gag against TSG101 
and Alix. And whether having additional flexible domains present on the protein, inhibit or 
aid the Gag-UEV (UEV being the Gag interacting domain is TSG101) interaction or Gag-Alix 
interaction throughout the assembly and maturation process. This maturation process of 
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Figure 4. 1: 
Global lattice maps of HIV particles. 
Positions of hexameric unit cells are marked 
with hexamers. Hexamers are colored 
according to cross-correlation on a scale 
from low (red) to high (green). Maps are 
shown in perspective such that hexamers 
on the rear surface of the particle appear 
smaller. (A) Lattice maps for immature HIV 
particles. The side of the particle toward the 
viewer lacks ordered Gag. (B) Close-up of 
defects in immature Gag lattice. (C) Lattice 
maps for in-vitro-assembled Gag particles. 
(D) Close-up of defects in in-vitro-assembled 
particle lattice 3 
HIV-1 is an important drug class constituted in 
anti-HIV therapy, targets the PR which causes 
production of immature virus particles which 
are non-infectious  
In the immature form the Gag-protein shell is 
made up of ordered hexameric protein via the 
capsid domains with the MA domain 
anchored through the viral membrane. These 
hexameric Gag proteins form a truncated 
sphere, which contains irregular defects 3. 
These Gag protein form a lattice which keeps 
growing with characteristic curvature and 
incorporating new protein molecules (Fig: 
4.1). The size of the particle is dictated by the 
curvature and the flexibility of the protein. It 
is understood that within the host cell the 
recruitment of ESCRT proteins may help to 
leave large gaps in the shell after completion 
of the budding process 3. 
The PR cleavage is highly efficient and 
ordered, any mutations that affect the 
cleavage efficiency prove to be highly 
detrimental to maturation and infectivity 183. 
Cleavage by the PR causes a significant 
change in the morphology of the immature 
virion. As a result of the first cleavage the two 
intermediate produced are p39MA-CA-sp1 and 
p15NC-sp2-p6. Which are then further cleaved by 
the PR to give the mature domains in an 
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infectious virion. Any change in the sequence or timing of this ordered cleavage process can 
prove fatal for virus maturation45,184. 
Recent advances in cryo-EM and X-Ray crystallography techniques have helped us in 
understanding some of these rearrangements within the CA domain. The CA is made up of 
two independently folded domains, the N-terminal and the C-terminal domains. These two 
domains are flexibly linked and help in creating a hexagonal capsid lattice. The conformation 
is stabilised by three different interaction between the CA molecules; six fold symmetric 
NTD-NTD interaction that results in formation of the hexameric rings, the NTD-CTD 
reinforces the hexamer and a homodimeric CTD-CTD that help in linking the hexamers into a 
lattice 132,185. In order to form the mature fullerene cone, the CA requires insertion of 
pentamers into the lattice that close the ovoid by inducing acute surface curvature. Thus the 
capsid shell is made up of 250 hexamers and 12 pentamers of the CA protein (fig 4.1). 
 
Figure 4.2: 
 Stereo view of the final molecular dynamics equilibrated all-atom capsid model comprising 
216 CA hexamers (blue, NTD; orange, CTD) and 12 CA pentamers (green)132  
The homo dimeric interface in the CTD-CTD interaction is mediated by an α-helix interface 
known as helix-9. Going from immature CA to mature CA the CTD-dimerization is still 
mediated by helix 9, but the relative orientation of the two CA monomers changes (fig 4.2). 
This change is also accompanied by dramatic rearrangement of CA-NTD during maturation 
which would cause all interactions within the immature lattice to break 55. The mechanisms 





 The arrangement of the CA lattices in immature and mature HIV particles. CA-NTD and CA-
CTD domains are coloured in cyan/blue and orange/red, respectively. b, The structures of CA 
dimers from the lattices in a are shown in top and orthogonal views. CA-CTD interactions are 
always mediated by helices 9, although the dimer rotates around this interaction in the 
transition from the immature to the mature. CA-NTD interactions are in each case entirely 
different. 55 
Similarly the crystal structure of the mature MA protein has revealed two functionally and 
structurally distinct regions; N-terminal globular domain which is involved in membrane 
binding, assembly, envelope incorporation and a C-terminal regional projecting away from 
the structure, which is involved in viral entry 127. Studies have indicated that the MA forms 
trimers in solution and these trimers combine to form a hexamer of trimers on interaction 
with the lipid membrane containing PI(4,5)P2 186. Although these matrix trimers do not play 
a significant role in virus assembly, their disruption causes loss of Env incorporation and thus 
viral infectivity 187. During the assembly and maturation process how the matrix 
trimerization influence the assembly of the still connected capsid, which forms hexamers 








Figure 4.4:  
A schematic of precursor Gag, intermediate and mature protein forms names. Pr55 cleaved 
into p39 and p15; p15 and p39 further get cleaved yielding the mature viral proteins p17, 
p24, and p7.  
As both CA and MA undergo structural rearrangements to accommodate their mature form, 
it would be interesting to observe their conformation in the intermediate p39MA-CA-sp1. It 
would help us in understanding the sequence of structural re-arrangements that the 
proteins undergo from the precursor to the final mature form. 
Advances in cryo-EM/ET and X-ray crystallography techniques have paved a way for the 
high-resolution structures of the assembled immature and mature capsid along with the 
matrix trimer. The biggest challenge however remains, obtaining a structure of the full 
length Gag. A better understanding of the considerations that underlay various interactions 
occurring during assembly and maturation can only be deciphered through understanding 
the structure of individual Gag domains in the precursor form. Now with recombinant 
production of Pr55 Gag, we have taken a major step towards obtaining X-ray crystallography 
or cryo-EM structure for the full length Gag. But advances still need to be made to increase 
the yield of the protein for structural studies, as well as deduce the optimal condition for a 
monodisperse population.  
In order to find a systematic approach to give us the best chance for getting an informative 
answer on Gag structural studies, we have screened various Gag interacting partners for a 
stable complex assembly. These complexes include host interacting proteins such as ESCRT 
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proteins and nucleic acids. At the same time we have raised monoclonal antibodies in mice 
against recombinant Pr55Gagand selected a number of different hybridoma clones as 
determined by their binding characteristics to Pr55Gag as well as intermediate and mature 
forms. Antibodies have been used previously to reduce surface entropy of protein 
molecules. Also antibody Fab fragments have been used successfully to crystallize multi-
domain proteins, membrane proteins and flexible proteins that had previously not been 
able to be crystallised by themselves. These antibody Fab: protein complex molecular 
structures have revealed suitable surface features and architecture, protein/protein and/or 
protein/ligand interaction sites that potentially represent new drug targets. Using a 
combination of structure-based drug design and fragment-based drug discovery now allows 
for the rapid identification of lead compounds as part of the drug discovery process towards 















4.2. Methods related to this chapter 
4.2.1. mAb production 
Monoclonal antibodies against Pr55Gag and intermediate p39MA-CA-sp1 were raised in mice in 
collaboration with Monash Antibody Technologies Facility. Selected hybridoma clones raised 
against Pr55Gag were thawed at 37⁰C, swabbed with 70 % ethanol, diluted and cultured in 
Hybridoma Serum-Free Cell Culture Media (Life Technologies) at 37 ⁰C in a 5 mL shaker flask 
with 10 %  FBS (Fetal Bovine Serum).  
4.2.2. mAb purification 
Cells were harvested by spinning down cultures at 340 xg for 5 mins. The supernatant was 
collected and filtered through 0.2 micron filter (Millipore). mAb was captured on 5ml GE 
HiTrap Protein G HP using Bio-Rad ProfiniaTM Protein Purification system pre-equilibrated 
with 1X TBS (Tris Based Saline 50 mM Tris.HCl, pH 7.4 and 150 mM NaCl)  at 2ml/min. The 
column was then washed with 1X TBSA and eluted with Citrate buffer (pH 3.5) into 3M Tris 
pH 8 for neutralizing. Eluted antibody was then loaded on a Superdex 200 16/60 column in 
Tris base saline Bio-Rad DuoFlowTM systems and the peak fractions were collected with a 
BioFrac fraction.  
4.2.3. Differential scanning fluorimetry 
 This fluorescence-based assay developed by Pantoliano and coworkers (US patent 
6,020,141) was performed using S1000™ Thermal Cycler (bio-rad). Solutions of 5 μM HPPK, 
10X Sypro Orange (Sigma-Aldrich) and different buffer solutions were added to the wells of 
the 96-well plate. The total well volume used was 30 μL. The plate was heated from 20–99 
°C with a heating rate of 1.0 °C/min. The fluorescence intensity was measured with 
excitation/emission = 583/610 nm. The different buffer solutions tested were acetate 
(pH=4.0-4.5), citrate (pH=5.0), MES (pH=6.0-6.5), HEPES (pH=7.5-8.0), Tris (pH 8.0-8.5) 
containing different additives such as NaCl (50-300 mM), RE (arginine, glutamine acid) (50-
100 mM), CHAPS (1-5 %), glycerol (1-10 %), sorbitol (1-10 %) and combinations of aditives. 
Tm and ΔTm values were determined from the melting curves obtained with the help of Bio-
Rad CFX software. 
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4.2.4. Crystallization trials 
Nano-litre crystallization trials were performed at the CSIRO Collaborative Crystallisation 
Centre (C3), Parkville, Melbourne using a phoenix crystallization robot (Art Robbins 
instruments, Sunnyvale California, USA). Screening experiments were performed using a 
sparse matrix screen 188 at both 8⁰C and 20⁰C. The nano-liter crystallization experiments 
were setup using the sitting-drop method in 96 well Innovadyne SD-2 plates (IDEX 
corporation) with a reservoir containing 50μl precipitant solution. Each drop contained 
150nl protein solution (5-10 mg/ml) in a buffer of 20% w/v PEG (Polyethylene glycol) 8000 
pH8.0, 100mM CHES and 10mM DTT and 150 nl of reservoir buffer. The crystallisation 
experiments were then imaged 10 times over a 2 month period to monitor crystal formation 
and growth using the Formulatrix Rock Imager 1000. 
















4.3.  Results 
4.3.1. Increase in recombinant protein production using a biorector: 
Previously we have demonstrated we could produce 1 mg purified recombinant soluble 
Pr55Gag from a 1.0 L bacterial culture grown in a shake flask 189. We have since optimized the 
bacterial expression conditions using Terrific Broth supplemented with 50 μM ZnCl2, 
resulting in a 6-fold increase in Pr55Gag production. Using a 2.0 L bioreactor, defined media, 
and regulated growth conditions we have now been able to increase Pr55Gag production by 
more than 100-fold. An initial seed culture was added to the bioreactor to attain an OD600 of 
0.25.The OD600 was monitored over the duration of the bioreactor 22-23 hrs after 
inoculation and the final OD600 was recorder to be 65 (As described in Chapter 3).  
Large scale purification of Pr55Gag was carried out using a combination of immobilized metal 
affinity chromatography (IMAC) followed by size exclusion chromatography gel filtration 
(superdex 200 26x60 column). Size exclusion chromatogram indicates that the protein 
migrated at an apparent molecular weight of 150 kDa, and was similar to that observed with 






Figure 4.5:  
(a) Size exclusion chromatography (Superdex 200 26x60 column) profile of purified Pr55Gag 
with the apparent molecular weight markers in grey. Peak fractions were collected and 
analysed by SDS-PAGE (b) and Western blotting probed with an anti-HIV capsid antibody (c). 
 
The identity of the protein was confirmed by SDS-PAGE and Western blotting using an anti-
HIV capsid monoclonal antibody (fig 4.3 b and c). The purified Pr55Gag produced could be 
concentrated up to 2.5 mg/ml in 1M NaCl Tris buffer and was assessed to be > 95 % pure. 
Altogether, we achieved a yield of 120 milligrams of Pr55Gag from a 1.5 litre of bacterial 




4.3.2. Decreasing the pH of the buffer increases thermal stability and mono-
dispersity of Pr55Gag   
 
Figure 4.6:  
Thermal denaturation spectra of Pr55Gag in buffers containing different pH (a) and the first 
derivative of the melt curves (b). The Tm changes from around 54°C in pH 5.0 (red) to around 
36°C in pH 9.0 buffer (black). 
Pr55Gag produced using the bioreactor protocol could be concentrated to 2.5 mg/mL any 
further attempts to concentrate higher resulted in the protein precipitating out of solution. 
We used Differential Scanning Fluorimetry (DSF) to identify conditions to increases in the 
protein’s thermal stability as determined by melting temperature (Tm). There were no 
significant differences observed in the melting Tm at different salt concentrations (0.3 – 0.05 
M NaCl), however, there was a significant increase in Tm going from a basic pH 9.0 (Na2B4O7; 




Figure 4.7:  
Buffer exchange profile comparison of Pr55Gag in buffer with pH 5.0 and pH 8.0 (a). Peak 
fractions from buffer exchange (pH 5.0) were concentrated to 8 mg/ml and 3μl of sample 
was loaded onto an SDS-PAGE gel for analysis (b). 
In order to test the condition identified by DSF we buffer exchanged the purified Pr55 Gag 
into a low pH buffer using a desalting column (5ml sephadex G-25 superfine, GE). The 
recovery of protein was 4 fold higher in the 50mM NaOAc pH 5.0 buffer compared to 50 
mM Tris pH 8.0 buffer, under low salt conditions. The peak fractions following buffer 
exchange were collected and protein was concentrated upto 8 mg/ml. Protein was loaded 
onto a SDS-PAGE under reduced conditions for analysis (Fig 4.6). The monodispersity of the 
protein was also compared at different pH buffers using dynamic light scattering (Fig 4.7), 






Figure 4.8:  
The mass distribution based on dynamic light scattering and relative polydispersity of 
Pr55Gag in buffer with pH 5.0 (a) and buffer with pH 8.0 (b). Poly-dispersity of the protein 
decreases from around 35% in pH 8.0 to 17% in pH 5.0, suggesting an increase in mono-
dispersity at lower pH. 
 
 
Figure 4.9.:  
The mass distribution based on dynamic light scattering and relative polydispersity of 
Pr55Gag in buffer containing 10mM, 100mM and 150 mM NaCl at pH 5.0 (50mM NaOAc).  
Poly-dispersity of the protein in this case remained unchanged with increasing salt 
concentrations. 
Going from a concentration of 10mM NaCl, 100mM NaCl and 150 mM NaCl, the 
monodispersity of Gag remained un-changed (Fig 4.8). Suggesting the NaCl concentration 
did not have much effect on the monodispersity of the complex, based on our results from 
DLS experiments. 
4.3.3. Presence of excess detergent impedes bio-characterization of protein 
Recombinant Pr55Gag purified under low pH buffer (50mM NaOAc, Ph 5.0) conditions 
exhibits maximum solubility in the absence of NaCl. During size exclusion chromatography 
the lack of ionic charge provided by NaCl resulted in the protein non-specifically interacting 
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with the Superdex 200 column and eluted from the column much later than anticipated 
(Figure 3.7). This caused an issue in recognizing the protein peak during gel filtration 
purification process, as we cannot identify the correct eluent based on its approximate 
molecular weight. 
 
Figure 4.10:  
a. Size exclusion chromatography profile (Superdex 200 1660 column) of purified Pr55Gag in 
buffer containing no NaCl, expected elution volume is marked. Protein eluted after 
approximately 1.5 CV, suggesting it may have interacted non-specifically with the column 
matrix. Peak fractions analysed by SDS-PAGE (b). 
In order to overcome this obstruction we purified eluted protein from IMAC directly over a 
buffer exchange column. The protein obtained following the buffer exchange was then used 
for mass spec analysis and further DSF analysis. The mass spec analysis (data not shown), 
gave a high reading for multiple peaks at consistent molecular weight intervals which is a 
characteristic of having high concentration of detergent in buffer solution. This observation 
was further confirmed as the same sample under DSF also displayed a high fluorescence 




 Figure 4.11:  
Thermal denaturation spectra of Pr55Gag following buffer exchange. The high fluorescence 
reading signifies the presence of excess detergent in the protein. 
To overcome the issues of Tween-20 interfering with the interpretation of our results from 
mass spectroscopy and DSF, we purified Pr55Gag in the absence of 4% Tween 20 which is 
present in the cell lysis buffer (section 2.4.4). Although lack of detergent decreased the final 
yield of the protein by half the total amount, the eluted protein remained highly soluble and 
stable. The molecular weight of the purified protein was then confirmed by mass spec 
analysis, which in the absence of a detergent gave us a clear reading. A mass of 56749 (fig 
3.9) was obtained from the purified Pr55 Gag, which is 135.72 daltons less than expected 
molecular weight of 56883. This loss of 135 daltons can be attributed to the loss of a 
histidine residue from the C-terminal His-tag. 
 
Figure 4.12: 
Electrospray ionization mass spectroscopy of HIV-1 Pr55Gag, shows a molecular weight of 
56749.35 Da. The difference of 135 daltons from the expected molecular weight can be 





4.3.4. Final Optimized Pr55Gag purification protocol. 
Cell pellets (~200 g) were thawed and resuspended in 1.0 L of ice cold lysis buffer (50 mM 
NaOAC pH 5.0, 5 mM MgCl2, 10 mM imidazole, 10% (v/v) glycerol, 5 mM DTT) containing 
50,000 units of DNase I, 5 mM benzamidine-HCl and 1 mM PMSF. The cell suspension was 
homogenized (EmulsiFlex-C5 homogenizer, Avestin®) pre-chilled to 4 oC, three times at 700 
bar pressure. The lysate was clarified by centrifugation 12,000 g, 4°C, 30 min), and the 
supernatant filtered using a 0.45 μm Stericup® filter (Millipore). 
IMAC Purification 
The supernatant was loaded at 5 mL min-1 onto a 30 mL HisTRAP fast flow IMAC column 
(consisting of 6 x 5 mL cartridges connected in series; GE Healthcare) using a MINIPULS® 
peristaltic pump (Gilson®).  The column had previously been equilibrated with 5 column 
volumes (CV) binding buffer (50 mM NaOAc pH 5.0, 5 mM MgCl2, 10 mM imidazole, 10 % 
(v/v) glycerol, 5 mM DTT). The column was washed with 10 CV wash buffer (50 mM NaOAc 
pH 5.0, 5 mM MgCl2, 25 mM imidazole, 10 % (v/v) glycerol, 5 mM DTT) and bound proteins 
eluted with 5 CV elution buffer (50 mM NaOAc pH 5.0, 5 mM MgCl2, 250 mM imidazole, 10 
% (v/v) glycerol, 5mM DTT). Pr55Gag eluting from the IMAC column was concentrated to ~ 
3.0 mg mL-1 using a centrifugal concentrator (Amicon Ultra-15, 10,000 molecular weight cut-
off membrane; Millipore).  
Buffer Exchange 
The concentrated protein was then fractionated by Buffer Exchange using a HiTrapTM 
Desalting column (GE Healthcare) previously equilibrated in Desalt buffer (50 mM NaOAc pH 
5.0, 1 TCEP, pH 5.0) using a  ÄKTApurifier chromatography workstation (GE Healthcare). 
Peak fractions (UV 280nm) containing Pr55Gag were collected, pooled and concentrated to 5 





4.3.5. Pr55 Gag complex assembly 
Multidomain proteins like Pr55 Gag have various interacting partners within a host cell that 
stabilize the oligomeric structures. In order to form a stable complex assembly we analysed 
different Gag binding co-factors and interacting partners. 
4.3.5.1. Full length Gag displays a low affinity for UEV and ALIX v domain 
interactions. 
Previous studies have shown biophysical analysis of interactions between the UEV domain 
of ESCRT I and PTAP sequence containing a 9 amino acid peptide. The peptide bound to UEV 
domain with a Kd value of around 50 μM in solution 138. In a similar study, in vitro binding of 
HIV-1 p6 16 mer peptide containing the the LYPXnLXXL sequence bound to Alix V domain 
with a Kd of 5-6 μM 103. With the availability of recombinant full length Gag we wanted to 
look at similar interactions of UEV and Alix with Pr55 Gag using ITC method as described in 
Chapter 3. 
 
Figure 4. 13: 
 Isothermal calorimetry analysis of Pr55Gag (27 μM) into cell containing TSG101 UEV domain 
(a) (540 μM) and Alix V domain (b) (270 μM). 
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In both experiments we used 27 μM (1.5 mg/ml) of Pr55 Gag in the cell, injected with 540 μM 
of UEV (fig 3.10 a) (9 mg/ml) and 270 μM of Alix V domain (fig 3.10 b) (11 mg/ml) in 
separate experiments. In both cases the binding with Pr55Gag was observed to be low 
affinity. It is difficult to judge the exact Kd of the reactions based on the binding curves, as 
the low affinity nature and limiting aqueous solubility of the test compounds imposes 
practical limits on performing titrations at higher ligand and protein concentrations. Also 
keeping in mind these experiments were conducted before the optimization of Gag 
purification protocol in the absence of detergent, our next step would be to repeat these 
experiments with the new purification protocol.  
4.3.5.2. Pr55Gag forms a more stable complex with SL3 sequence than 
immature virus sequence. 
In our previous study (Chapter 3), we have shown that Pr55Gag gave us the highest affinity 
binding with SL3 RNA sequence and the immature virus sequence. In order to test the 
stability of the Gag-RNA complex, we conducted a DSF experiment to look at the melting 
temperature of the complex (Figure 3.11). The protein and RNA were both in a buffer 
containing 50 mM sodium acetate pH 5.0 at a ratio of 1% (w/w) which enabled us to keep 





 Thermal denaturation spectra of Pr55Gag in complex with Immature RNA (Green) and SL3 
RNA (Blue) (a) and the first derivative of the melt curves (b). The two peaks represent the 
complex formed between Gag and two different RNAs. The Tm for Gag-SL3 complex shows a 
higher Tm at around 44°C compared to 42 °C with the immature RNA, suggesting a more 
stable complex is formed between Gag-SL3. 
From this analysis we observed that Pr55Gag –RNA complex is less stable than Pr55Gag on its 
own. Hence we compared the two different RNA sequences in complex with Pr55Gag. 
Assuming these peaks were representing the Gag-RNA complex disassembly and Pr55 Gag 
only disassembly, Pr55Gag –SL3 complex gave a Tm of 44⁰C and Pr55 Gag –immature RNA 
complex gave us a Tm of 42⁰C. These data suggest Pr55Gag forms a more stable complex 
when it interacts with SL3 RNA sequence when compared to the complex formed with the 





Monoclonal antibody purification for stabilising Gag complexes with Fab fragments. 
Approximately 50 monoclonal antibodies were raised against recombinant Pr55Gag and the 
intermediate p39MA-CA-sp1 in collaboration with Monash Antibody Technologies Facility in 
mice. The clones were all negative for mycloplasma contamination, and were weaned into 
Hybridoma Serum Free medium. Based on their expression levels around 10 were selected 
for large scale expression and after further purification around 5 of them gave us good 
expression levels enough for analysis. These 5 antibodies were purified over a protein G-
sepharose column using a peristaltic pump. Binding of the monoclonal antibodies (mAb) to 
Pr55Gag were tested using a NiNTA biosensor at 25°C using a ForteBio biosensor system 
(ForteBio, Menlo Park, CA) (fig 4.14). 
 
Figure 4.15: 
 Binding affinities of different monoclonal antibodies against Pr55Gag using a label free 
system. The anti-CA 183 clone was used as a positive control. Clone13e2 showed 
approximately the highest affinity for Pr55Gag out of the 4 different clones examined. 
Based on our initial screening antibodies from clone 13e2 and 18c2 gave the highest affinity 
against Pr55Gag. These two antibodies would be ideal for purifying the antigen binding arm 
or Fab fragment and analyse the stability of the Gag-Fab complex formed. Hence our step is 
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to purify these fragments from the selected antibodies and look at their monodispersity and 
Tm using DLS and DSF. These fragments will then be used for crystallization trials with both 
Pr55Gag and p39MA-CA-sp1. 
4.3.6. P39MA-CA-sp1 crystallization trials 
Although structures of the mature matrix and capsid of HIV-1 Gag have been solved and 
explained in great details, but their orientation in the precursor form is still unclear. The 
intermediate Gag p39MA-CA-sp1, is one of the primary products formed after the first cleavage 
of full length Gag by PR. We purified recombinant p39MA-CA-sp1 using the bioreactor protocol 
and analysed it using gel filtration.  
 
Figure 4.16: 
Size exclusion chromatography (Superdex 200 26x60 column) profile of purified p39MA-CA-sp1 
with molecular weight markers in grey. Peak fractions were analysed by SDS-PAGE (b); and 
Western blotting, probed with anti-CA antibody (c). 
The purified p39MA-CA-sp1 which has a monomeric molecular weight of 41 kDa, eluted with an 
apparent molecular weight of ~110kDa. The peak fractions were then analysed using SDS-
PAGE and Western transfer (Figure 3.14). 
In order to determine a stable buffer conditions for p39MA-CA-sp1, we further screened various 





Figure 4.17:  
Thermal denaturation spectra of p39MA-CA-sp1 in buffers at different pH (a) and the first 
derivative of the melt curves (b). The Tm changes from around 52°C in pH 5.0 (red) to around 
42°C in pH 9.0 buffer (black). 
Similar to Pr55Gag, the intermediate p39MA-CA-sp1 also showed a higher Tm with decrease in 
pH. Going from a basic pH 9.0 to pH 5.0, the melting temperature increased from 42⁰C to 




Figure 4.18:  
Buffer exchange profile comparison of p39MA-CA-sp1 in buffer pH 5. (a). Peak fractions from 
buffer exchange (pH 5.0) were concentrated to 8 mg/ml and 1μl sample volume was loaded 
onto an SDS-PAGE gel for analysis (b). 
The pooled fractions were then ran over a desalting column for buffer exchange in to 
sodium acetate pH 5.0 buffer with 1mM TCEP. Peak fractions from the buffer exchange 
were pooled and concentrated up to 10 mg/ml, and 1 μl from the concentrated sample was 
ran over SDS-PAGE gel for analysis (Figure 3.16). Protein was found to be of greater than 
95% purity. 
As the purified p39MA-CA-sp1 displayed better solubility than the full length Pr55 Gag, 
crystallization trial of p39MA-CA-sp1 using vapour-diffusion method in a JCSG+ plate at 
temperatures of 8⁰C and 20⁰C were setup. Although we did observe crystals in few wells 




Figure 4.19:  
Crystallization trial wells containing CA (0.2M calcium chloride dehydrate, 0.1M Sodium 
cacodylate pH 6.5) , Zn (0.2M Zn acetate dehydrate, 0.1M Imidazole pH 8.0) and Li (0.2M 
Lithium sulfate, 0.1 M Bis-Tris pH 5.5) appeared to have crystal formed which on UV analysis 
did not show any fluorescence. These crystals could be salt crystals. 
In one of the wells of the crystallization plate at 20⁰C containing tert-butanol and 
polyethylene glycol 600 with trisodium citrate-citric acid at a pH of 5.5, we could see crystals 
forming by the 22nd day. They started to show fluorescence under UV light, which confirmed 






Figure 4.20:  
Crystallization trial of a well containing polyethylene glycol 600 with trisodium citrate-citric 
acid at a pH of 5.5 developed crystals that fluoresced under UV light, which grew in size over 
a period of two months. Suggesting these were protein crystals. 
Once the crystals stopped increasing in size, we looked at a few wells under a microscope 
for closer analysis. Crystals seemed to be small spherulites, which were quite small in size to 
be used for x-ray crystallography.  
 
Figure 4.21:  
On closer inspection the crystals looked like spherulites. 
These crystals were then crushed with glass beads and used as seeds for nucleation in more 
crystallization plates.  
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For further analysis we have setup more crystallization plates using the conditions that gave 
us these needle crystals, at the same time were looking at using the Fab fragments and 
other CA and MA interacting partners to use during trials. 
4.3.7. P39MA-CA-sp1 particle analysis using Transmission electron microscopy 
The intermediate p39MA-CA-sp1 purified at low pH and in the absence of any detergent was 
concentrated to 1.5 mg/ml. This sample was imaged under TEM using uranyl acetate, with 
the resulting images displaying a high background.  The sample was diluted 400 times, TEM 
was repeated with consistent particles observed around ~7 - 8 nm in size. This would be the 
approximate size expected for a complex in the 150 kDa – 200 kDa range.  
 
Figure 4.22:  
TEM analysis of p39MA-CA-sp1particles stained with uranyl acetate. The field view of the grid 
(a) showed a number of particles around 7-9 nm in size. When these small particles were 
magnified in (b) displayed an ordered structure. 
These samples would be ideal for cryo-EM single particle analysis, as having a consistent 




 Recombinant protein production for structural studies presents one of the most difficult 
and challenging tasks for heterologous expression in E.coli. For a conclusive study the 
protein needs to be in a native, active, soluble, pure and concentrated state. Multi domain 
proteins like HIV-1 Pr55Gag, specifically present a greater challenge for expression in E.coli 
due to their flexible nature and various interacting interfaces. Furthermore the propensity 
of full length Gag molecules to self-assemble through the CA and nucleic acid binding NC 
domain, increases the chances for the protein to form aggregates. 
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Due to the complexity caused by the fundamental characteristic of the full length Gag 
protein, the majority of the structural and biophysical studies have been conducted on 
either mature Gag domains or the more stable Pr50 Gag ∆p6 mutant.  This leaves us with an 
incomplete molecular picture of Gag as it goes through assembly. We have purified full 
length recombinant HIV Gag for the first time to our knowledge, details of which are given in 
chapter 2.  The quantity of protein obtained from our published protocol, still makes it time 
consuming to make enough for protein intensive structural and biophysical assays. In order 
to overcome this hurdle we have used a bioreactor fermenter. By changing the protocol we 
increased the total yield by 2 log fold, which is sufficient for any in vitro studies for protein 
analysis. A comparison on the quantity and purity of the final yield of Gag, using different 
published methods has been given in Table 2. 
Using shake flask and Luria broth medium for recombinant protein production limits the 
amount of cell density as the bacterial cells start making toxins and running out of nutrients. 
Using a fed-batch technique described previously 190, we can limit the production of acetic 
acid at high cell mass concentration. One of the main reasons for toxicity caused by acetic 
acid is lowering of pH in the medium, which causes an increase in acid diffusing freely across 
lipid bilayers and lowering cytoplasmic pH 191. Using the optimised protocol, we can monitor 
the pH of media during growth of cells and maintain a neutral pH. Other important factors 
like sustained antibiotic levels and presence of protease inhibitors that prevent degradation 
of protein of interest also help in increasing protein expression. Use of other additives such 
as zinc help stabilise the zinc fingers present in NC region of Gag during expression. We also 
achieved complete lysis of cells using a high pressure cell homogeniser which helped us in 
better recovery of the protein from cells. These factors work in coordination with each other 
to make the protein expression and purification process much more efficient.   
Structural analysis of HIV-1 Gag has been limited to the mature CA and MA domain. Which 
leaves us with many unanswered questions about the rearrangement of domains in the 
precursor or immature form of Gag. In order to get structural information using X-ray 
crystallography or cryoEM studies, we require homogenous single molecules or mono-
dispersed complexes.  Moreover both the techniques require a high concentration of 
protein either to have enough molecules for a lattice formation in a crystal form or have 
enough number of larger complexes for imaging. Thus in order to stabilise the Pr55Gag and 
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p39MA-CA-sp1 we screened different buffer conditions, and in both cases the proteins showed 
a higher Tm at lower pH. This indicated the stability of the proteins increased in a more 
acidic pH environment. This decrease in pH in turn gives the protein molecules a positive 
surface charge that might contribute to the protein-protein interactions and keep the 
molecules from misfolding into aggregates. This positive surface charge might also 
contribute to the protein molecules interacting with the dextran beads in a Superdex 200 
size exclusion column. As a result of this interaction the protein does not elute from the 
column based on its apparent molecular weight. Using a different substrate for the beads 
circumvents this issues, but this technique also leaves residual detergent (Tween-20) from 
our lysis buffers. As a result of high detergent, during DSF analysis the dye used for 
fluorescence in the assay binds to the detergent in the solution rather than the hydrophobic 
residues in the protein molecule. This gives a false reading during the experiment and also 
prevents correct reading during other analytical assays such as mass spectrometry. 
Removing the Tween-20 from the purification process seems to overcome this problem, but 
it also decreases the soluble protein yield.  
Perhaps screening less intrusive detergents like CHAPS would be a good step forward in 
order to keep the protein yield high, while the conditions remain compliant with assays. 
Regardless of the presence of detergent, the proteins still seemed stable in the low pH 
buffer and could be concentrated up to 10 mg/ml. 
Recent studies 3,55 have shown how the during virion genesis the capsid domain undergoes 
drastic rearrangements. But in the immature form, the MA and CA domain are interlinked 
which could affect the CA rearrangement. As p39MA-CA-sp1 is the first cleavage product of the 
full length precursor Gag which has both the MA and CA domain, the structural elucidation 
of this intermediate could help us in understanding the virion genesis better. Crystallization 
trials with p39MA-CA-sp1 result in formation of spherulites, which were then used as 
microseeds for further optimization. These microseeds can act as nucleation points and 
perhaps give us diffractable crystals for structural analysis using X-ray crystallography. At the 
same time optimization around the conditions that gave us these spherulites needs to be 
done to further scout the ideal conditions for crystal formation. Although as the crystals 
took a long time in the plates to grow, it might be taken into consideration that these 
crystals might be a product of proteolytic processing within the p39MA-CA-sp1. Hence these 
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crystals can only be confirmed as the intermediate p39MA-CA-sp1 after looking at them under 
X-ray beams. 
Recently when we analysed the p39MA-CA-sp1 particles under TEM, we saw consistent 
particles with defined symmetry.  Although there is certain optimizing to be done to get a 
more homogenous population of particles, this is a good step forward to give us good single 
particle analysis for structural analysis.  
Structural elucidation of the full length Pr55Gag presents a different challenge as it contains 
the nucleic acid binding NC domain and the ESCRT binding p6 domain. Inside the infected 
host cell, the Pr55Gag molecules are stabilised with the help of multiple complex interactions. 
Hence we studied these various interactions with nucleic acids and other interacting 
proteins to stabilise the recombinant protein in vitro. At a concentration of 1% w/w to the 
protein, SL3 RNA gave us possible complex, but the Tm showed the complex to be less 
stable than the protein only molecules. At the 1 % w/w concentration the protein to RNA 
molecule ratio is around, 1 RNA molecule for every 12 Gag molecules. This calculation might 
explain why we still see a melting peak at the expected protein only Tm, as we have multiple 
Pr55Gag molecules which remain unbound to the RNA. Perhaps increasing the RNA 
concentration will incorporate more Pr55 Gag and in turn stabilise the Gag-RNA complex. It 
would also be important to look at the full length HIV-1 RNA and the psi binding region (SL1-
SL4) region binding to Gag, as previous studies have shown the role of each stem loop 
contributes to Gag-RNA binding 68. Although the amount of full length HIV-1 RNA available 
for such studies is limited.  
Considering all available options, we will have to look at a strategy which forms a 
homogenous Gag complex using multiple Gag interactions at once. This can include a 
combination of ESCRT protein, HIV-1 RNA and the Fab fragments from purified monoclonal 
anti-Gag antibodies.  
4.5 Conclusion 
 
Our study has successfully increased the yield of soluble recombinant Gag expressed in 
bacteria by 2 log folds. Biophysical characterization studies using purified Pr55Gag have 
identified a highly stable buffer condition, which enables the protein to be soluble even in 
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high concentrations required for structural analysis. The intermediate p39MA-CA-sp1 has been 
shown to form semicrystalline spherulites which gives a major suggestion for the condition 
required to look at the protein structure using X-ray crystallography. At the same time we 
have optimised conditions that are a major step forward toward single particle analysis for 
the p39MA-CA-sp1 intermediate Gag. Although we did set up crystallization trials for Pr55Gag no 



















HIV-1 Gag is the major component that orchestrates the virus assembly, maturation and 
budding process. During the maturation process, Gag interacts with various host cell 
proteins and viral nucleic acids alike. Our study has shown for the first time how to purify 
large quantities of full-length recombinant Pr55Gag using bacterial E.coli system. Using the 
purified recombinant protein we can examine how Gag-RNA interactions play out as Gag 
undergoes cleavage during maturation. This in vitro system helps in specifically looking at 
the role of Gag protein during assembly, as under in vivo conditions it is much harder to 
control Gag conformation of Gag due to the multiple binding partners present within a cell. 
We have also identified key conditions that help stabilise the precursor Pr55Gag and the 
intermediate p39MA-CA-sp1 in solution, which is one of the biggest constraints of structural 
studies of the protein using techniques such as X-ray crystallography and cryo-microscopy. 
Previous studies in the field have used the truncated Pr50Gag ∆p6 to show that Gag exists in a 
folded over compact conformation by bringing its two ends in closer 3D space 192,193. 
However, upon addition of inositol phosphate (a heavily phosphorylated compound 
resembling the head groups of membrane-localized phospholipids) changes the size of the 
particles to a more authentic size (~100 nm) 193. This folded over conformation of Pr50Gag ∆p6 
was also observed when the protein was bound to a biomimetic membrane in the absence 
of nucleic acids. Presumably via the basic domains in the MA and NC regions 156, both of 
which have been known to interact with the HIV-1 RNA194. But here it was shown that the 
MA has a strong preference for lipids whereas NC shows high affinity for nucleic acids which 
causes the MA to separate from nucleic acid in the presence of lipid head groups. This in 
turn causes the protein to form a rod shaped conformation which is observed in authentic 
VLPs 77. Substrate interactions are often context dependent, and it is clear that the NC 
domain also interacts with membrane of ESCRT family, such as Alix195. The interactions of 
ESCRT protein TSG101 and viral protein Vpr via the p6 domain 196 is likely to influence the 
overall folding of Gag during viral assembly. Thus using combination of biophysical and 
imaging techniques, it would be interesting to observe whether similar conformation switch 
would occur with the full-length recombinant Pr55Gag in the presence of ESCRT proteins 
and/or Vpr. As this would give us a better idea of how the protein behaves during viral 
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assembly, a question that remained unanswered in previous studies due to the lack of p6 
domain in the recombinant protein.   
Within the infected cell, the host cell cytoplasmic protein CypA and TRIM5α bind to the 
capsid core and disrupt the uncoating process 17,65.  Residues within the CA region of Gag, 
responsible for CypA interaction and packaging have been identified using a recombinant CA 
protein 197. Similarly recombinant Pr50 Gag ∆p6 has been utilised to analyse NC interactions 
with tRNALys3 and APOBEC3G 198,199. The NC binding to tRNALys3 enhances tRNALys3 annealing 
during retroviral DNA synthesis and APOBEC3G (deaminase-editing enzyme) encapsidation 
through its interaction with NC. As the virus undergoes maturation, structural 
rearrangement occurs to facilitate proper assembly of the mature domain structure. This 
rearrangement causes   surface residues and interfaces to expose and hide in different 
conformations, which in turn affects interaction with other proteins such as CypA, Trim5 α, 
Lys tRNA synthetase and APOBEC3G. The assembly of the virus and its interaction with 
multiple host factors occurs almost simultaneously, as a result it gets difficult to observe 
each individual interaction. By using recombinant Pr55Gag studies we can inspect each of the 
host cell protein interactions with Gag in detail. These observations will also help us in 
understanding which interacting surface is exposed based on the proteins that bind to 
precursor Gag. 
Interaction between Gag and viral RNA has cascading effects that initiate the formation of 
the HIV virus. Hence it is of great importance for us to understand the nature of forces that 
regulate and stabilise the reaction. Combining structural information with the energetics of 
this binding can help us in identifying the key interface contributing to this interaction. 
Hence we used ITC which is the most quantitative means to study the thermodynamic 
properties of Gag-RNA interaction. We have used the Pr55Gag to look at the thermodynamic 
effects of Gag-RNA binding using 20-mer oligonucleotide peptides of different RNA 
sequences. The use of the 20-mer oligonucleotide was ideal in a practical way for us, as they 
are quite stable, inexpensive and have low turnover rate for synthesis. Moreover previous 
studies have shown that 20 nucleotides are sufficient to induce Gag oligomerization 146. 
Having an in-depth knowledge of Gag-RNA binding and the Gag-Gag multimerization, we 
can now analyse if binding partners like Staufen 1 affect the thermodynamics of Gag-RNA 
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binding. Staufen 1 has been known to bind to the NC domain of Gag through its zinc fingers 
in the cytoplasm and in doing so influences Pr55Gag assembly200.  
In vitro assembly studies looking at Gag-RNA binding have for the most part focused on the 
binding of either non-specific nucleic acids such as yeast tRNA or shorter segments of the 
HIV-1 viral RNA. This is in general due to the limitation in generating large quantities of full 
length genomic RNA for analysis. Our collaborators now have an efficient method for 
synthetic synthesis of HIV-1 RNA of around 600 bases. Using our recombinant Pr55Gag, Abd 
El-Wahab Et al. have shown that the specific regions within the HIV-1 RNA specifically the 
internal loop sequence within the SL1 is the primary binding site which shows the highest 
affinity towards Gag and this region is crucial for RNA packaging in the virus 68,201. Following 
on from these studies it would be beneficial to look at the conformation of Pr55Gag bound to 
the full length HIV-1 RNA in solution and whether having a longer RNA sequence including 
the SL1 causes any structural rearrangement from the folded over conformation of Gag to 
the elongated form which is better suited for particle formation 192.  
The ITC experiments in our studies have given us a detailed mechanism of thermodynamic 
parameters that affect Gag-RNA binding during maturation. The understanding of this 
mechanism can be greatly strengthened by using the complete Gag binding RNA sequence. 
The SL1 has been shown to play an important role in RNA packaging and at the same time 
confers the selectivity of gRNA68. Using mutational studies within the Gag binding domain of 
HIV-1 RNA we can look at binding affinities of different region within the RNA to Pr55Gag and 
compare thermodynamic parameters.  
The NC domain is responsible for RNA binding, which drives Gag-Gag assembly in the 
cytoplasm. During maturation NC undergoes conformational change in order to facilitate 
encapsidation of the genomic RNA within the virus and remains bound to the RNA inside the 
capsid core of mature virus 202.   
Maturation brings further rearrangements in CA domain, in order to facilitate formation of 
the capsid core. In the immature form the helix 9 present on CA-CTD, changes its orientation 
relative to the two monomers of CA, this facilitates rearrangement of CA-NTD from 
immature to mature form causing all interactions within the immature lattice to break 55. 
The MA also undergoes rearrangement to form trimers for binding to the cholesterol rich 
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membrane 55,202. The structural details available of the matrix trimer and the immature as 
well as the mature capsid are available through studies which looked at the individual 
domains without any interlink. While during the maturation process immature Gag is a 
collection of the CA, MA, NC and p6 domains which are interlinked. In order to understand 
the complete maturation process we need to discern rearrangements of these domains in 
coordination with each other.  Hence we decided to analyse the p39MA-CA-sp1 intermediate 
Gag along with the Pr55Gag to better understand the changes in domain organization 
through the maturation process. The intermediate p39MA-CA-sp1 is the first cleavage product 
during the maturation, and contains the MA region connected to the CA. In mature forms 
the CA attains a hexameric conformation, whereas the MA forms a trimer. Analysing the 
structure of p39MA-CA-sp1 will help us in understanding the capsid domain and matrix 
arrangement in the immature form when compared to the mature MA and capsid core55. At 
the same time the analysis might bring to light any assistance the capsid rearrangement 
provides to the PR for binding. These conclusions can only be made through revealing the 
structure of domains in their immature, intermediate and mature forms. 
Structural studies of multidomain protein like p39MA-CA-sp1 and Pr55Gag, have an inherent 
issue of being intrinsically disordered which makes them difficult to analyse by techniques 
such as X-ray crystallography or cryo-EM. Both these techniques require large amounts of 
protein at relatively high concentrations. To form stable homogenous complex for cryo-EM 
or protein crystals for X-ray crystallography the individual molecules need to be packed in a 
repeating array with a monodisperse population, this requires certain level of uniformity in 
the protein population. This uniformity of a protein sample is strongly influenced by the 
composition of the buffer the protein is in. Multiple domains of Gag contribute to the 
uniformity of its molecule. At the same time we have also considered some host cell 
interacting proteins which potentially can help in stabilising the Gag protein complex. 
With the lower pH buffer conditions, the intermediate Gag p39MA-CA-sp1 gave us some 
promising spherulites which grew into small needle looking crystals, although they were too 
small for X-ray crystallography. In our future experiments we need to optimize the condition 
which gave us the small crystals and whether certain other additives or p39MA-CA-sp1 binding 
co-factors can give us a diffractable crystal. At the same time using TEM we were able to 
observe small complexes with p39MA-CA-sp1, our next step would be look at the sample 
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samples under cryo-EM. With a more homogenous population of the complexes we should 
be able to determine the structure of these molecules with cryo-EM based single particle 
analysis. 
With Pr55Gag which contains additional interacting interface and domains, we looked at 
complex formation of Gag with the immature RNA sequence, SL3 RNA sequence, and two 
interacting ESCRT proteins TSG101 UEV domain and Alix V domain.  
We observed that the Pr55Gag interaction with both UEV and Alix V domain displayed far less 
affinity than the previous studies looking at just the p6 domain interaction with UEV and Alix 
V domain 39,100,103. Although the follow up experiments did display how the presence of 
excess detergent would have hindered these interactions with Pr55Gag, we would have to 
repeat similar type of experiments with recombinant Gag purified in the absence of 
detergent.  
The Gag bound with SL3 sequence complex showed a higher Tm than the Gag bound with 
Immature RNA sequence complex, but still had a lower Tm than the Gag only control. 
Suggesting that Gag-SL3 sequence complex although more stable than Gag-Immature RNA 
sequence complex had less stability than Gag only molecules. Looking at complex formation 
of Pr55Gag with either the full length HIV-1 RNA or the RNA containing Gag binding sites, 
would be also a good option as the secondary structures within the RNA might stabilize the 
protein. Looking at such complexes under negative staining or transmission electron 
microscopy can confirm formation of such complexes and analyse the structures under cryo-
EM. To follow up from these observations in the future, we plan to look at Gag complexes 
using the 600 nt HIV-1 RNA containing the complete Gag binding domain. Having a longer 
RNA to bind to, might cause Gag to form the fold back conformation, which could be 
observed by atomic structure determination. 
To stabilise Gag complex, we have purified monoclonal antibodies raised against the 
recombinant Pr55Gag in mouse model. Antibodies can offer valuable scaffolding for proteins 
to form a stable complex. The approach of using antibodies to aid in crystallization have 





Since the first reported case of HIV infection in humans, there has been an explosion of 
information on Gag. Various new insights have been gained into the CA structure at both 
immature and mature level of virus cycle as well as the role RNA plays at the structural level. 
Even then completely understanding the various changes Gag undergoes structurally during 
maturation is a complex task. This task is further convoluted by the various synergistic 
reactions that occur within the host cell as the virus matures. This complexity is stated by 
the fact that out of the numerous anti-retrovirals now available for treatment of HIV, none 
target Gag. Now with the availability of recombinant Gag we can simplify the host cell 
protein and Gag-Gag interactions by controlling the parameters in an in vitro setting.  
The current treatments even though effective, have the likelihood of becoming less efficient 
in case of resistance. Moreover, as HIV infection moves towards a more chronic manageable 
condition through availability of new antiretroviral we are observing the long term side 
effects of the current drugs.  
With this study we have now identified the key conditions that will help us in understanding 
the dynamic movement of the structural HIV domains and further our steps towards 
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